

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016368
Article Type:	Research
Date Submitted by the Author:	10-Feb-2017
Complete List of Authors:	<p>Yang, Fen Chen, Jianping; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science Miao, Mao-Hua; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices Yuan, Wei; Shanghai Institute of Planned Parenthood Research, Reproductive Epidemiology, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices; Li, Lin Liang, Hong; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices Ehrenstein, Vera Li, Jiong</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Mental health
Keywords:	MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, NEUROPATHOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Risk of autism spectrum disorder in offspring following paternal use of selective**
5
6 **serotonin reuptake inhibitors before conception**
7

8 Fen Yang^{1,2}; Jianping Chen¹; Maohua Miao¹; Wei Yuan¹; Lin Li¹; Hong Liang¹; Vera
9 Ehrenstein²; Jiong Li²
10
11
12

13
14
15
16 **Author Affiliation**
17

18 ¹Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
19 Shanghai, 200032, China
20
21

22 ²Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle
23 43-45, DK-8200 Aarhus N, Denmark
24
25
26
27
28
29
30

31 **Corresponding Author**
32

33 Hong Liang, MD, PhD
34

35 Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
36 #779 Lao Hu Min Road, Shanghai, 200032, China.
37
38

39 Email: lucylhen@163.com;
40

41 Phone number: 86 -21-64771683
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract**Objective**

The present study aimed to examine the association between paternal selective serotonin reuptake inhibitors (SSRIs) use before conception and the risk of autism spectrum disorder (ASD) in offspring.

Design

A population-based cohort study

Methods

Based on Danish national registers, we conducted a cohort study of 669,922 children born from 1998 to 2008, with follow-up throughout 2013. The children whose fathers used SSRIs during the last 3 months prior to conception were identified as the exposed. Cox regression model was used to estimate the hazard ratio (HR) for ASD in children.

Results

Compared with unexposed children, the exposed had a 1.43-fold higher risk of ASD (HR=1.43, 95% confidence interval [CI]: 1.18-1.74) after adjusting for potential confounders. When extending the exposure window to 1 year before conception, the adjusted HR (aHR) of ASD in children of fathers who used SSRIs only from the last year till the last 3 months prior to conception and who used SSRIs both before and during the last 3 months prior to conception was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72), respectively. Whereas, the risk in children of fathers who used SSRIs only during the last 3 months prior to conception decreased and became

nonsignificant (aHR=1.17, 95%CI: 0.75-1.82).

Conclusions

Our findings suggested no substantial increase in the risk of ASD in the offspring attributable to paternal SSRIs use before conception.

Strengths and limitations of this study

- This is the very first study that investigates the link between paternal antidepressants use and ASD risk in children.
- A number of potential confounders, including sociodemographic factors as well as parental psychiatric history, can be adjusted for based on the availability of national health registry data.
- Actual use of SSRIs by fathers during the time period of interest may not be validated.
- Those children who received the diagnosis of ASD from private psychiatrists or remained undiagnosed at the end of the follow-up may not be identified as ASD

Introduction

Depression is a common mental health problem that affects approximately 350 million people worldwide¹. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and other anxiety-related disorders. However, an increasing body of evidence suggests that prenatal exposure to SSRIs is associated with adverse obstetrical and neonatal outcomes²⁻⁴. In addition, recent studies have indicated a possible link between prenatal SSRI exposure and neurobehavioral problems in children^{5,6}.

Autism spectrum disorder (ASD) is one of the major neurodevelopmental disorders characterized by impairments in reciprocal social interaction, communication, and repetitive or stereotypic behavior⁷. The estimated prevalence of ASD has dramatically increased from less than 1 in 2,000 children in 1960s to approximately 1 in 145 children today^{8,9}. Both genetic and environmental risk factors may contribute to ASD¹⁰. Recently, maternal use of SSRIs during pregnancy has been reported to be associated with an increased risk of ASD in children¹¹⁻¹³.

If maternal SSRI exposure during pregnancy plays a role in fetal, even in child's, development, an extended effect of earlier exposure on gamete, particularly human sperm, is biologically plausible. Therefore, the potential role of paternal SSRI use in ASD should also be taken into consideration. Studies in the Nordic countries show that one-third of the fathers used prescription drugs during the last 6 months prior to conception¹⁴, and approximately 1.4% of fathers were dispensed SSRIs during the last 3 months prior to conception^{15,16}. Although the information regarding the

1
2
3
4 potential effects of SSRI use by fathers is limited, the hypothesis of an increased risk
5
6 of adverse pregnancy or neonatal outcome associated with paternal drug exposure is
7
8 not new. Evidence from experimental studies suggests that paternal exposure to a
9
10 broad range of xenobiotic agents may induce reproductive and developmental
11
12 abnormalities in the subsequent offspring, e.g., spontaneous abortions, congenital
13
14 malformations, growth retardation, neurobehavioral deficits, or carcinogenesis¹⁷⁻¹⁹.
15
16 Epidemiologic studies have also shown that certain pharmacological agents used by
17
18 fathers before conception may increase the risk of spontaneous abortions, birth defects
19
20 or childhood cancers^{20,21}. The potential mechanisms behind the male-mediated effects
21
22 include: 1) genetic or epigenetic changes with direct disturbances in spermatocytes; 2)
23
24 indirect effects by transmission of the xenobiotic agents to the female via the seminal
25
26 fluid^{17, 18}. Several studies have indicated the adverse effects of paternal SSRIs use,
27
28 including impaired semen quality and abnormal sperm DNA fragmentation^{22, 23},
29
30 which has been reported to be associated with diminished fertility, adverse pregnancy
31
32 outcomes, and an increased risk of childhood disease²⁴.
33
34
35
36
37
38
39
40

41 Little is known on whether paternal SSRIs use before conception contributes to
42
43 the risk of ASD in offspring. We conducted a population-based cohort study to
44
45 examine the association between paternal SSRIs use during the last 3 months prior to
46
47 conception and risk of ASD in offspring, utilizing data from national Danish health
48
49 registries.
50
51
52
53
54
55

56 **Methods**

57
58
59
60

Study Population

This study was based on several national registers in Denmark. Each Danish resident is assigned a unique personal identification number (a 10-digit civil registration system number used in all registries), which enables accurate linkage of national registries at the individual level²⁵. The Danish Medical Birth Registry (DMBR) contains records of all deliveries in Denmark since 1973 and includes information about gestational age at birth from 1978²⁶. Using the DMBR data, we identified a cohort of all singletons born alive in Denmark during the period of January 1, 1998 through December 31, 2008 (n=687,580). We excluded children without linkage to their father (n=16,955) or their mother (n=74), with missing parity (n=208), and with missing or extreme values of gestational age (≤ 23 weeks or ≥ 45 weeks, n=421). A total of 669,922 children were included in the analysis.

Data on SSRIs use

Information on SSRIs use was drawn from the Danish National Prescription Registry (DNPR)²⁷. Since 1995, this registry has recorded all redeemed prescriptions in Denmark with the following information: the civil registration number of the patient, the dispensing date, the medication code (the WHO Anatomical Therapeutic Chemical (ATC) classification system), the number of packages prescribed, and the number of doses units in package. Selective serotonin reuptake inhibitors use was identified based on ATC codes: fluoxetine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), fluvoxamine (N06AB08), and escitalopram (N06AB10). It is estimated that spermatogenesis takes approximately 74 days²⁰,

1
2
3
4 therefore we chose the last 3 months prior to conception as the exposure window to
5
6 cover the susceptible time period. A child was considered exposed if the dispensing
7
8 date fell within the specified exposure window or the number of days for which the
9
10 SSRIs medication was supplied overlapped any portion of the exposure window.
11
12 Children born to fathers who had no prescriptions for SSRIs and no supply overlap
13
14 during the entire exposure window were considered unexposed. The date of
15
16 conception was estimated by subtracting gestational age from the date of delivery.
17
18 Data on paternal SSRIs use during the last two years prior to the conception were
19
20 extracted for further analyses. We also retrieved the information about maternal SSRIs
21
22 use during the pregnancy.
23
24
25
26
27

28 **Autism spectrum disorders**

29
30 Autism spectrum disorders in children were identified by using the Danish Psychiatric
31
32 Central Research Register (DPCRR) and the Danish National Patient Register
33
34 (DNPR). The DPCRR contains diagnostic information on every admission from
35
36 psychiatric hospitals and psychiatric wards in general hospitals in Denmark since
37
38 1969, and includes data on all outpatient visits and emergency room contacts since
39
40 1995²⁸. The DNPR has collected data on all inpatients from all somatic hospitals in
41
42 Denmark since 1977 and outpatients from 1995²⁹. The combined data from the two
43
44 registries were used to identify all children diagnosed with ASD. During the study
45
46 period, the diagnosis of ASD was based on the International Classification of
47
48 Diseases, 10th version (ICD-10) codes of F84.0 (Childhood autism), F84.1 (Atypical
49
50 autism), F84.5 (Asperger syndrome), F84.8 (other pervasive developmental
51
52
53
54
55
56
57
58
59
60

1
2
3 disorders) and F84.9 (unspecified pervasive developmental disorders). The quality of
4
5 the childhood autism diagnosis has been validated and the diagnoses could be
6
7 verified in 94% of the children with a record in the DPCRR³⁰. Children were
8
9 followed up from birth till first diagnosis of ASD, death, emigration, or December 31,
10
11 2013, whichever came first.
12
13

14 15 16 **Covariates**

17
18 Using the Danish nationwide health registers, we retrieved data on characteristics that
19
20 may be associated with offspring ASD or paternal SSRIs use. For each child, we
21
22 obtained information on calendar year of birth, gender of the child, birth weight,
23
24 Apgar score at 5 minutes, gestational age, maternal parity, maternal age at child birth,
25
26 paternal age at child birth and maternal smoking status during pregnancy from the
27
28 DMBR. Parents' psychiatric history prior to birth of the index child was obtained
29
30 from DPCRR by ICD-8 codes 290-315 from 1977 to 1993 and ICD-10 codes F00-F99
31
32 from 1994 onward. Furthermore, we identified parents diagnosed with affective
33
34 disorders before birth of child (specifically, ICD-8 codes 296.09, 296.19, 296.29,
35
36 296.39, 296.99, 298.09, 298.19, 300.49, and 301.19, and ICD-10 codes F30-F34 and
37
38 F38-F39) using the DPCRR.
39
40
41
42
43
44
45

46 47 **Statistical Analysis**

48
49 Cox proportional-hazards regression models were used to estimate the hazard ratios
50
51 (HRs) and 95% confidence intervals (CIs) of ASD in children following exposure to
52
53 paternal SSRIs use before conception.
54
55
56
57
58
59
60

1
2
3
4 We adjusted for variables as following: the calendar year of birth (1998-2000,
5
6 2001-2003, 2004-2006, 2007-2008), gender of the child (boy, girl), parity (1, 2, ≥ 3),
7
8 parental age at child birth (≤ 25 , 26-30, 31-35, and > 35 years), maternal smoking
9
10 status during pregnancy (yes or no), maternal history of psychiatric disorders before
11
12 birth of child (yes or no), maternal antidepressants use during pregnancy (yes or no)
13
14 in model 1. We additionally adjusted for paternal history of psychiatric disorders
15
16 before birth of child (yes or no) in model 2. Models were also run with the exclusion
17
18 of those children with missing data for covariates.
19
20
21
22
23

24 To distinguish the direct effects of SSRIs use from the effects of the indication of
25
26 SSRIs use, we extended the exposure window to 1 year before conception. We then
27
28 re-categorized the exposed children into three subgroups: children of fathers who used
29
30 SSRIs 1) only from the last year till the last 3 months prior to conception (former
31
32 SSRIs users); 2) only during the last 3 months prior to conception (current SSRIs
33
34 users); 3) both before and during the last 3 months prior to conception (both former
35
36 and current SSRIs users). The reference group consisted of those children born to
37
38 fathers who never used SSRIs medication through the last year before conception.
39
40
41
42
43

44 The stratified analysis was performed to examine whether the association between
45
46 paternal SSRIs use and ASD in children differed by gender. We also restricted the
47
48 analyses to children whose mothers neither received antidepressant medication during
49
50 pregnancy nor had affective disorder before birth of child. To further distinguish the
51
52 effect of SSRIs medication from that of paternal affective disorders, we performed
53
54
55
56
57
58
59
60

1
2
3 stratified analyses according to paternal history of affective disorder before birth of
4
5
6 the index child.
7

8
9 Besides, to control for unmeasured family-related confounding factors, we
10
11 re-conducted a sibling study by restricting to families with more than one child and
12
13 with at least one child with paternal SSRIs preconception exposure. Using the
14
15 stratified Cox proportional-hazards regression, we then compared exposed siblings to
16
17 unexposed siblings to estimate the association between paternal SSRIs use before
18
19 conception and ASD in children.
20
21

22
23
24 All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary,
25
26 North Carolina, USA).
27

28 29 **Results**

30
31 Among the 669,922 singletons included in the study, 6,870 (1.03%) children were
32
33 born to fathers who had redeemed a prescription for SSRIs during the last 3 months
34
35 prior to conception. During the study period, a total of 7,577 children were diagnosed
36
37 with ASD. The median age at diagnosis of ASD was 6.77 years (interquartile range:
38
39 4.84 to 9.48 years). Characteristics of the study population are shown in Table 1.
40
41 Compared with the unexposed group, there were a higher proportion of exposed
42
43 children born in later calendar years. Fathers in exposed group were more likely to be
44
45 older at child birth and to have a history of psychiatric disorder (including affective
46
47 disorder) before birth of child. Mothers of exposed children were characterized as
48
49 having higher parity, being more likely to be older at child birth, to use
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 antidepressants during pregnancy, and to have a history of psychiatric disorder before
5
6 birth of child.
7

8
9 Among 61,555 person-years of follow-up, we identified 104 cases of ASD in
10
11 children born to fathers who used SSRIs during the last 3 months prior to conception
12
13 (incidence rate: 169 per 100,000 person-years). This incidence rate corresponded to a
14
15 62% increased risk of ASD compared with the unexposed group (Table 2). The
16
17 adjusted HR (aHR) of ASD was 1.54 (95% CI: 1.27-1.88) after adjusting for potential
18
19 confounders in model 1. After paternal psychiatric history was further adjusted for in
20
21 model 2, the estimate was 1.43 (95%CI: 1.18-1.74). When extending the exposure
22
23 window to the last one year prior to conception, the aHR for ASD in children of
24
25 fathers who were former users only and who were both former and current users was
26
27 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72), respectively. However, the
28
29 increased risk decreased and became nonsignificant among children of fathers who
30
31 were only current users (aHR=1.17, 95%CI: 0.75-1.82, model 2, table2).
32
33
34
35
36
37
38

39 The risk estimates of ASD were similar for both boys and girls, regardless of the
40
41 exposure (Table S1). When we restricted analyses to children whose mothers neither
42
43 used SSRIs during pregnancy nor had affective disorder before birth of child, the
44
45 results did not change essentially (Table S2).
46
47
48

49 When the analyses were stratified by paternal affective disorder before birth of the
50
51 index child, in children born to fathers with a history of affective disorder, there was
52
53 no association between paternal SSRIs use before conception and ASD in the
54
55 offspring (model 2: aHR=1.10, 95%CI: 0.61-1.98). For children whose father without
56
57
58
59
60

1
2
3
4 affective disorder, the patterns of associations remained similar to those of the main
5
6 analyses (Table 3).
7

8
9 In the sibling analysis, we identified 5,479 families with more than one child and
10
11 with at least one child with paternal SSRIs use before conception (Table 4). The risk
12
13 of ASD in exposed children was similar when compared with their unexposed siblings
14
15 (aHR=1.04, 95%CI: 0.94-1.14).
16
17

18 19 **Discussion**

20
21 In this large population-based cohort study, we observed an increased crude risk of
22
23 ASD in the offspring following paternal use of SSRIs during the last 3 months prior to
24
25 conception. However, the risk attenuated after adjusting for a number of potential
26
27 confounders, especially fathers' psychiatric conditions. When extending the exposure
28
29 window to one year before conception, the ASD risk persisted among children born to
30
31 former users but not current users. In addition, among children born to father with
32
33 affective disorder, no association was observed. Finally, we performed a sibling
34
35 analysis which allowed for better control of unmeasured familial confounding and no
36
37 difference in the ASD risk was found among exposed children and their unexposed
38
39 siblings. Taken as a whole, our results did not support that paternal SSRIs use before
40
41 conception could increase the risk of ASD in children.
42
43
44
45
46
47

48
49 Recently, concerns have been raised regarding the risk of ASD in the offspring
50
51 associated with prenatal exposure to SSRIs. Three previous human studies have
52
53 suggested that in utero exposure to antidepressants would increase the risk of ASD in
54
55 children¹¹⁻¹³, although another two studies using the Danish registers have reported no
56
57
58
59
60

1
2
3 significant association^{31,32}. Basic neuro-biologic studies have showed that prenatal
4
5
6 SSRIs administration may be part of a causal pathway to ASD by operating directly
7
8
9 on the developing brain^{33,34}. Considering the detrimental effect of SSRIs on sperm^{22,}
10
11
12 ^{23,35}, paternal SSRIs use before conception may also cause adverse effects on
13
14 pregnancy outcomes. However, till now, only one study have suggested that SSRIs
15
16 administration to male rats could induce deterioration in fertility and fetal outcomes
17
18 (including weight gain, organ weights and feed consumption)³⁶. To our knowledge,
19
20
21 our study is the first to investigate the link between paternal antidepressants use and
22
23
24 ASD risk in children. Considering the limited number of ASD cases and the
25
26
27 challenges posed by confounding, further studies are needed to corroborate the
28
29
30 findings.

31
32 In the present study, the increased risk of ASD observed in former users but not in
33
34 current users implied that indications for paternal SSRIs use may account for the
35
36 observed association between paternal SSRIs use and ASD in children, which was
37
38 supported by previous studies suggesting that parental depression and other
39
40 psychiatric disorders might be associated with the risk of autism in children³⁷⁻³⁹.
41
42
43 When we further looked into those children without paternal affective disorder (the
44
45 main indication for SSRIs) before birth of child, similar patterns of association to the
46
47 main analyses were found. Thus, in addition to affective disorders, other indications
48
49 related to SSRIs use may also contribute to the observed association.
50
51
52

53
54 Our study has several methodological strengths. One strength was that the linkage
55
56 of several nationwide health registries in Denmark enabled us to conduct a large
57
58
59

1
2
3
4 cohort study with virtually complete follow-up. The definition on exposure to SSRIs
5
6 was based on a national registry, which eliminated the risk of recall bias caused by
7
8 self-report. Another strength was that the information on ASD diagnosis was obtained
9
10 independently of exposure measurement, which could also mitigate the information
11
12 bias. Furthermore, the availability of health registry data enabled us to adjust for a
13
14 number of potential confounders including sociodemographic factors as well as
15
16 parental psychiatric history.
17
18
19

20
21 Limitations need to be considered when interpreting the results of our study.
22
23 Firstly, we were unable to validate actual use of SSRIs by fathers during the time
24
25 period of interest because we relied on medical records of dispensed prescriptions.
26
27 This may lead to misclassification of exposure status because some people may not
28
29 take the medication or may take it later. Nevertheless, the misclassification was most
30
31 likely non-differential, which could bias the association toward null. Besides, some
32
33 patients may receive SSRIs treatment during inpatient admissions which are not
34
35 included in the prescription registry. We expect this problem to be minor since those
36
37 inpatients usually have severe psychiatric disorders and are more likely to continue
38
39 treatment after discharge. Secondly, the 3-month cut-off point was set based on the
40
41 fact that spermatogenesis takes approximately 70-90 days in humans. Whereas it may
42
43 be possible that SSRIs drugs induce sperm damage at the very primitive stage.
44
45 However, the results did not change markedly after extending the putative exposure
46
47 period to the last 6 months prior to conception (data not shown). Thirdly, ASD in
48
49 children was ascertained through the DNPR and the DPCRR, which did not include
50
51
52
53
54
55
56
57
58
59
60

1
2
3 those children who received the diagnosis of ASD from private psychiatrists or
4
5 remained undiagnosed at the end of the follow-up. However, the prevalence of ASD
6
7 in our cohort was 1.13%, which was similar to that reported in the United States
8
9 during the study period (1.14%)⁴⁰. Hence the bias introduced by case identification
10
11 was expected to be minimal.
12
13
14

15 16 **Conclusions**

17
18 Our evidence does not support that paternal SSRIs use before conception increases the
19
20 risk of ASD in the offspring, but implicates that paternal underlying indications
21
22 related to SSRIs use, or other unmeasured confounding factors may play a role.
23
24
25
26
27

28 **Footnotes**

29
30 This cohort study was approved by the Danish Data Protection Agency (Record No.
31
32 2013-41-2569).
33
34

35 **Contributors:** HL had full access to all the data in the study and took responsibility
36
37 for the integrity of the data and the accuracy of the data analysis. HL, WY and JL
38
39 conceptualized and designed the study. FY conducted the statistical analysis. HL, PC
40
41 and FY interpreted the results and FY drafted the initial manuscript. All authors
42
43 reviewed the manuscript and approved the final version.
44
45
46

47 **Funding:** The study was supported by the National Natural Science Foundation of
48
49 China (81428011), the National Key Research and Development Program of China
50
51 (2016YFC1000505), the European Research Council
52
53 (ERC-2010-StG-260242-PROGEURO), Nordic Cancer Union (2015-176673), Danish
54
55
56
57
58
59
60

Council for Independent Research (DFF-6110-00019), and Karen Elise Jensens Fond (2016).

Competing interests: The authors declare that they have no conflict of interest.

Statement of the independence of researchers from funders: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The researchers were independent from the funders.

Ethical approval: For this type of study formal consent is not required.

Data sharing statement: No additional data are available.

Reference

1. Organization WH. Depression [fact sheet no. 369]. 2012. As of September. 2015;30.
2. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. *American journal of obstetrics and gynecology*. 2006;194(4):961-966.
3. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. *Archives of pediatrics & adolescent medicine*. 2009;163(10):949-954.
4. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. *Bmj*. 2009;339:b3569.
5. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. *Archives of pediatrics & adolescent medicine*. 2007;161(1):22-29.
6. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *American Journal of Psychiatry*. 2012;169(11):1165-1174.
7. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *The lancet*. 2006;368(9531):210-215.
8. Rutter M. Incidence of autism spectrum disorders: Changes over time and their meaning*. *Acta paediatrica*. 2005;94(1):2-15.
9. Hill AP, Zuckerman K, Fombonne E. Epidemiology of autism spectrum disorders. *Translational Approaches to Autism Spectrum Disorder: Springer* 2015:13-38.
10. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders*. *Annu Rev Public Health*. 2007;28:235-258.

11. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. *Journal of autism and developmental disorders*. 2014;44(10):2558-2567.
12. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. *Archives of general psychiatry*. 2011;68(11):1104-1112.
13. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. 2013.
14. Schirm E, Pedersen L, Tobi H, et al. Drug use among fathers around time of conception: two register based surveys from Denmark and The Netherlands. *Pharmacoepidemiology and drug safety*. 2004;13(9):609-613.
15. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population - based cohort study of 106 000 pregnancies in Norway 2004 - 2006. *British journal of clinical pharmacology*. 2008;65(5):653-660.
16. Crijns I, Bos J, Knol M, et al. Paternal drug use: before and during pregnancy. *Expert opinion on drug safety*. 2012;11(4):513-518.
17. Sever LE. Male-mediated developmental toxicity. *Toxicology & Applied Pharmacology*. 1993;14(1):506-513.
18. Friedler G. Paternal exposures: Impact on reproductive and developmental outcome. An overview. *Pharmacology Biochemistry & Behavior*. 1996;55(4):691-700.
19. Anderson D, Schmid TE, Baumgartner A. Male-mediated developmental toxicity. *Asian journal of andrology*. 2014;16(1):81.
20. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. *Basic & clinical pharmacology & toxicology*. 2008;102(2):176-181.
21. Engeland A, Børge T, Daltveit AK, et al. Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340 000 pregnancies using Norwegian population - based databases. *British journal of clinical pharmacology*. 2013;75(4):1134-1141.
22. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. *Fertility and sterility*. 2010;94(3):1021-1026.
23. Safarinejad MR. Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay. *The Journal of urology*. 2008;180(5):2124-2128.
24. Lewis S, Aitken R. DNA damage to spermatozoa has impacts on fertilization and pregnancy. *Cell and tissue research*. 2005;322(1):33-41.
25. Pedersen CB, Gøtzsche H, Møller JØ, et al. The Danish civil registration system. *Dan Med Bull*. 2006;53(4):441-449.
26. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Danish medical bulletin*. 1998;45(3):320-323.
27. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scandinavian journal of public health*. 2011;39(7 suppl):38-41.
28. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. *Scandinavian journal of public health*. 2011;39(7 suppl):54-57.
29. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. *Danish medical bulletin*. 1999;46(3):263-268.
30. Lauritsen MB, Jørgensen M, Madsen KM, et al. Validity of childhood autism in the Danish

- 1
2
3 Psychiatric Central Register: findings from a cohort sample born 1990–1999. *Journal of autism and*
4 *developmental disorders*. 2010;40(2):139-148.
- 5 31. Christensen J, Parner ET, Vestergaard M. Antidepressant exposure in pregnancy and risk of autism
6 spectrum disorders. *Clinical epidemiology*. 2013;5:449-459.
- 7 32. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy
8 and risk of autism. *New England Journal of Medicine*. 2013;369(25):2406-2415.
- 9 33. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects
10 on behavior and serotonin circuitry. *Neuropsychopharmacology*. 2006;31(1):47-57.
- 11 34. Bonnin A, Levitt P. Fetal, maternal and placental sources of serotonin and new implications for
12 developmental programming of the brain. *Neuroscience*. 2011;197:1.
- 13 35. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. *Urology*.
14 2007;69(1):185. e185-185. e187.
- 15 36. Elmazoudy R, Abdelhameed N, Elmasry A. Paternal dapoxetine administration induced
16 deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male
17 rats. *International Journal of Impotence Research*. 2015;27(6).
- 18 37. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism
19 spectrum disorders in the offspring. *Pediatrics*. 2008;121(5):e1357-e1362.
- 20 38. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, parental
21 psychiatric history, and socioeconomic status. *American journal of epidemiology*.
22 2005;161(10):916-925.
- 23 39. Jokiranta E, Brown AS, Heinimaa M, et al. Parental psychiatric disorders and autism spectrum
24 disorders. *Psychiatry research*. 2013;207(3):203-211.
- 25 40. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism
26 spectrum disorder among children in the US, 2007. *Pediatrics*. 2009;124(5):1395-1403.
- 27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table1. Baseline Characteristics of the study population

Characteristic	Paternal SSRIs use during the last 3 months prior to conception (N=6,870)	No paternal SSRIs use during the last 3 months prior to conception (N=663, 052)
Calendar Year of birth, No. (%)		
1998-2000	1,021(14.9)	185,784(28.0)
2001-2003	1,526(22.2)	179,952(27.1)
2004-2006	2,305(33.5)	178,664(27.0)
2007-2008	2,018(29.4)	118,652(17.9)
Gender, No. (%)		
Boy	3,549(51.7)	340,194(51.3)
Girl	3,321(48.3)	322,858(48.7)
Birth Weight (g), No. (%)		
<2500	278(4.1)	22,315(3.4)
2500-3250	1,729(25.2)	154,494(23.3)
3250-4000	3,582(52.1)	348,853(52.6)
4000-8000	1,243(18.1)	132,343(19.9)
Unknown	38(0.5)	5,047(0.8)
Parity, No. (%)		
1	2,693(39.2)	282,895(42.7)
2	2,433(35.4)	250,496(37.8)
≥3	1,744(25.4)	129,661(19.5)
Preterm Birth, No. (%) (<37 weeks)		
No	6,489(94.4)	630,851(95.1)
Yes	381(5.6)	32,201(4.9)
Apgar score at 5 minutes, No. (%)		
0-7	91(1.3)	8,224(1.2)
8-9	442(6.4)	39,941(6.0)
10	6,269(91.3)	607,634(91.7)
Unknown	68(1.0)	7,253(1.1)
Maternal age at child birth (years), No. (%)		
≤25	958(13.9)	99,273(15.0)
26-30	2,238(32.6)	244,419(36.9)
31-35	2,386(34.7)	225,610(34.0)
>35	1,288(18.8)	93,750(14.1)
Paternal age at child birth (years), No. (%)		
≤25	364(5.3)	47,490(7.2)
26-30	1,434(20.9)	180,612(27.2)
31-35	2,395(34.8)	242,702(36.6)
>35	2,677(39.0)	192,248(29.0)

Table 1. Baseline Characteristics of the study population (continued)

Maternal smoking status^a, No. (%)		
No	4,326(63.0)	477,574(72.0)
Yes	1,334(19.4)	106,233(16.0)
Unknown	1,210(17.6)	79,245(12.0)
Maternal AD use during pregnancy, No. (%)		
No	6,548(94.0)	653,496(98.6)
Yes	412(6.0)	9,556(1.4)
Maternal history of Affective disorder, No. (%)		
No	6,607(96.2)	654,234(98.7)
Yes	263(3.8)	8,818(1.3)
Paternal history of Affective disorder, No. (%)		
No	6,099 (88.8)	659,639(99.5)
Yes	771(11.2)	3,413(0.5)
Maternal history of psychiatric disorder, No. (%)		
No	6,175(89.9)	626,840(94.5)
Yes	695(10.1)	36,212(5.5)
Paternal history of psychiatric disorder, No. (%)		
No	5,092 (74.1)	630,990(95.2)
Yes	1,178(25.9)	32,062(4.8)

Abbreviations: SSRI, selective serotonin reuptake inhibitor; N, number; AD, antidepressant drugs;

^a Maternal smoking information was missing among those children born from 2007 to 2008.

Table 2. Association between paternal SSRIs use before conception and ASD in offspring

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,473	6,765,205	Ref	Ref	Ref
Use during the last 3 months prior to conception	104	61,555	1.62(1.33-1.96)	1.54(1.27-1.88)	1.43(1.18-1.74)
No use during the last 1 year prior to conception	7,429	6,736,654	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	71	39,422	1.71(1.35-2.16)	1.66(1.31-2.09)	1.54(1.21-1.94)
Use only during the last 3 months prior to conception	20	14,738	1.29(0.83-2.00)	1.24 (0.80-1.93)	1.17(0.75-1.82)
Use both before and during the last 3 months prior to conception	57	35,946	1.52(1.17-1.97)	1.43(1.10-1.86)	1.32(1.02-1.72)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 3. Association between paternal SSRIs use before conception and ASD in offspring born to fathers diagnosed with affective disorder or not

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Fathers with affective disorder					
No use during the last 3 months prior to conception	58	30,908	Ref	Ref	Ref
Use during the last 3 months prior to conception	14	6,625	1.17(0.65-2.09)	1.10(0.61-1.98)	1.10(0.61-1.98)
No use during the last 1 year prior to conception	53	28,033	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	8	4,082	1.07(0.51-2.25)	1.08(0.51-2.30)	1.08(0.51-2.30)
Use only during the last 3 months prior to conception	2	1,164	0.91(0.22-3.75)	0.89(0.21-3.75)	0.89(0.21-3.75)
Use both before and during the last 3 months prior to conception	9	4,254	1.16(0.57-2.35)	1.10(0.55-2.22)	1.10(0.55-2.22)
Fathers without affective disorder					
No use during the last 3 months prior to conception	7,415	6,752,899	Ref	Ref	Ref
Use during the last 3 months prior to conception	90	36,329	1.57(1.27-1.93)	1.52(1.23-1.87)	1.45(1.18-1.79)
No use during the last 1 year prior to conception	7,376	6,714,926	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	63	37,973	1.69(1.32-2.17)	1.64(1.28-2.11)	1.57(1.23-2.02)
Use only during the last 3 months prior to conception	18	7,354	1.26(0.79-2.00)	1.23(0.77-1.95)	1.19(0.75-1.88)
Use both before and during the last 3 months prior to conception	48	28,974	1.45(1.09-1.93)	1.38(1.04-1.84)	1.32(0.99-1.76)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 4. Paternal SSRI use before pregnancy and ASD in exposed and unexposed siblings from 5,479 families

Paternal SSRIs use before conception	Number of offspring no.	Offspring with ASD no.	Hazard Ratio (95% CI)	
			Crude	Model 1 ^a
No use during the last 3 months prior to conception	2,792	45	Ref	Ref
Use during the last 3 months prior to conception	2,687	23	1.08(1.01-1.16)	1.04(0.94-1.14)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for sex, parity, mother age, father age, maternal smoking, maternal AD use during pregnancy

TablesS1. Association between paternal SSRIs use before conception and ASD in offspring: analyses stratified by gender

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Boys					
No use during the last 3 months prior to conception	6,005	3,459,592	Ref	Ref	Ref
Use during the last 3 months prior to conception	84	31,642	1.61(1.30-2.00)	1.55(1.25-1.92)	1.44(1.16-1.79)
No use during the last 1 year prior to conception	5,969	3,444,956	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	58	20,031	1.74(1.34-2.25)	1.69(1.30-2.19)	1.58(1.22-2.05)
Use only during the last 3 months prior to conception	18	7,622	1.42(0.89-2.26)	1.39(0.87-2.21)	1.31(0.83-2.09)
Use both before and during the last 3 months prior to conception	44	18,623	1.44 (1.07-1.93)	1.36(1.01-1.84)	1.26(0.94-1.71)
Girls					
No use during the last 3 months prior to conception	1,468	3,305,613	Ref	Ref	Ref
Use during the last 3 months prior to conception	20	29,914	1.63(1.05-2.53)	1.54(0.99-2.40)	1.41(0.90-2.20)
No use during the last 1 year prior to conception	1,460	3,291,698	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	13	19,390	1.61(0.93-2.78)	1.53(0.88-2.64)	1.37(0.79-2.38)
Use only during the last 3 months prior to conception	2	7,116	0.67(0.17-2.69)	0.64(0.16-2.55)	0.59(0.15-2.36)
Use both before and during the last 3 months prior to conception	13	75,323	1.84(1.06-3.17)	1.74(1.01-3.01)	1.59(0.92-2.75)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table S2. Association between paternal SSRI use before conception and ASD in offspring born to mother who neither received antidepressant medication during pregnancy nor had affective disorders before birth of child

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,184	6,627,720	Ref	Ref	Ref
Use during the last 3 months prior to conception	91	57,081	1.55(1.26-1.91)	1.57(1.28-1.93)	1.45(1.18-1.79)
No use during the last 1 year prior to conception	7,144	6,600,852	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	64	37,032	1.67(1.30-2.13)	1.68(1.31-2.15)	1.56(1.22-1.99)
Use only during the last 3 months prior to conception	16	13,634	1.13(0.69-1.85)	1.15(0.71-1.89)	1.08(0.66-1.77)
Use both before and during the last 3 months prior to conception	51	33,283	1.50(1.13-1.97)	1.50(1.13-1.97)	1.38(1.05-1.82)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history

^b Model 1 further adjusted for father psychiatric history

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	9

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	20
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-11
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	19
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016368.R1
Article Type:	Research
Date Submitted by the Author:	19-May-2017
Complete List of Authors:	<p>Yang, Fen; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science; Aarhus Universitetshospital, Department of Clinical Epidemiology</p> <p>Chen, Jianping; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science</p> <p>Miao, Mao-Hua; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Yuan, Wei; Shanghai Institute of Planned Parenthood Research, Reproductive Epidemiology, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Li, Lin; Shanghai Institute of Planned Parenthood Research</p> <p>Liang, Hong; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Ehrenstein, Vera; Aarhus Universitetshospital</p> <p>Li, Jiong; Aarhus Universitetshospital, Department of Clinical Epidemiology</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Mental health
Keywords:	MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, NEUROPATHOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Risk of autism spectrum disorder in offspring following paternal use of selective**
4 **serotonin reuptake inhibitors before conception: a population-based cohort**
5 **study**
6
7
8
9

10 Fen Yang^{1,2}; Jianping Chen¹; Maohua Miao¹; Wei Yuan¹; Lin Li¹; Hong Liang¹; Vera
11 Ehrenstein²; Jiong Li²
12
13
14
15

16
17
18 **Author Affiliation**
19

20 ¹Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
21 Shanghai, 200032, China
22
23

24 ²Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle
25 43-45, DK-8200 Aarhus N, Denmark
26
27
28
29

30
31
32
33 **Corresponding Author**
34

35 Hong Liang, MD, PhD
36

37 Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
38 #779 Lao Hu Min Road, Shanghai, 200032, China.
39
40

41 Email: lucylhcn@163.com;
42

43 Phone number: 86 -21-64771683
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective

The present study aimed to examine the association between paternal selective serotonin reuptake inhibitors (SSRIs) use before conception and the risk of autism spectrum disorder (ASD) in offspring.

Design

A population-based cohort study

Methods

Based on Danish national registers, we conducted a cohort study of 669,922 children born from 1998 to 2008, with follow-up throughout 2013. The children whose fathers used SSRIs during the last 3 months prior to conception were identified as the exposed. Cox regression model was used to estimate the hazard ratio (HR) for ASD in children.

Results

Compared with unexposed children, the exposed had a 1.43-fold higher risk of ASD (HR=1.43, 95% confidence interval [CI]: 1.18-1.74) after adjusting for potential confounders. When extending the exposure window to 1 year before conception, the adjusted HR (aHR) of ASD in children of fathers who used SSRIs only from the last year till the last 3 months prior to conception and who used SSRIs both before and during the last 3 months prior to conception was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72), respectively. Whereas, the risk in children of fathers who used SSRIs only during the last 3 months prior to conception decreased and became

nonsignificant (aHR=1.17, 95%CI: 0.75-1.82).

Conclusions

The increased risk of ASD in the offspring associated with paternal SSRIs use before conception may be attributable to the underlying indications.

Strengths and limitations of this study

- This is the very first study that investigates the link between paternal antidepressants use and ASD risk in children.
- A number of potential confounders, including sociodemographic factors as well as parental psychiatric history, can be adjusted for based on the availability of national health registry data.
- Actual use of SSRIs by fathers during the time period of interest may not be validated.
- Those children who received the diagnosis of ASD from private psychiatrists or remained undiagnosed at the end of the follow-up may not be identified as ASD case.

Introduction

Depression is a common mental health problem that affects approximately 350 million people worldwide¹. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and other anxiety-related disorders. However, an increasing body of evidence suggests that prenatal exposure to SSRIs is associated with adverse obstetrical and neonatal outcomes²⁻⁵. In addition, recent studies have indicated a possible link between prenatal SSRIs exposure and neurobehavioral problems in children^{2, 6-10}, which may be due to the biological mechanisms (i.e. dysfunctional serotonin signaling)¹¹. Whereas several studies have suggested that the previously observed association between prenatal SSRIs exposure and neurodevelopmental diseases might be due to confounding by related indications¹²⁻¹⁵.

Autism spectrum disorder (ASD) is one of the major neurodevelopmental disorders characterized by impairments in reciprocal social interaction, communication, and repetitive or stereotypic behavior¹⁶. The estimated prevalence of ASD has dramatically increased from less than 1 in 2,000 children in 1960s to approximately 1 in 145 children today^{17, 18}. Both genetic and environmental risk factors may contribute to ASD¹⁹. Recently, maternal use of SSRIs during pregnancy has been reported to be associated with an increased risk of ASD in children^{10, 20-23}.

If maternal SSRIs exposure during pregnancy plays a role in fetal, even in child's, development, an extended effect of earlier exposure on gamete, particularly human sperm, is biologically plausible. Therefore, the potential role of paternal SSRIs use in

1
2
3 ASD should also be taken into consideration. Studies in the Nordic countries show
4
5 that one-third of the fathers used prescription drugs during the last 6 months prior to
6
7 conception²⁴, and approximately 1.4% of fathers were dispensed SSRIs during the
8
9 last 3 months prior to conception^{25, 26}. Although the information regarding the
10
11 potential effects of SSRI use by fathers is limited, the hypothesis of an increased risk
12
13 of adverse pregnancy or neonatal outcome associated with paternal drug exposure is
14
15 not new. Evidence from experimental studies suggests that paternal exposure to a
16
17 broad range of xenobiotic agents may induce reproductive and developmental
18
19 abnormalities in the subsequent offspring, e.g., spontaneous abortions, congenital
20
21 malformations, growth retardation, neurobehavioral deficits, or carcinogenesis²⁷⁻²⁹.
22
23 Epidemiologic studies have also shown that certain pharmacological agents used by
24
25 fathers before conception may increase the risk of spontaneous abortions, birth defects
26
27 or childhood cancers^{30,31}. The potential mechanisms behind the male-mediated effects
28
29 include: 1) genetic or epigenetic changes with direct disturbances in spermatocytes; 2)
30
31 indirect effects by transmission of the xenobiotic agents to the female via the seminal
32
33 fluid^{27, 28}. Several studies have indicated the adverse effects of paternal SSRIs use,
34
35 including impaired semen quality and abnormal sperm DNA fragmentation^{32, 33},
36
37 which has been reported to be associated with diminished fertility, adverse pregnancy
38
39 outcomes, and an increased risk of childhood disease³⁴.
40
41
42
43
44
45
46
47
48
49

50 Little is known on whether paternal SSRIs use before conception contributes to
51
52 the risk of ASD in offspring. We conducted a population-based cohort study to
53
54 examine the association between paternal SSRIs use during the last 3 months prior to
55
56
57
58
59
60

1
2
3 conception and risk of ASD in offspring, utilizing data from national Danish health
4 registries.
5
6
7
8
9

10 **Methods**

11 **Study Population**

12
13
14 This study was based on several national registers in Denmark. Each Danish resident
15 is assigned a unique personal identification number (a 10-digit civil registration
16 system number used in all registries), which enables accurate linkage of national
17 registries at the individual level³⁵. The Danish Medical Birth Registry (DMBR)
18 contains records of all deliveries in Denmark since 1973 and includes information
19 about gestational age at birth from 1978³⁶. Using the DMBR data, we identified a
20 cohort of all singletons born alive in Denmark during the period of January 1, 1998
21 through December 31, 2008 (n=687,580). We excluded children without linkage to
22 their father (n=16,955) or their mother (n=74), with missing parity (n=208), and with
23 missing or extreme values of gestational age (≤ 23 weeks or ≥ 45 weeks, n=421). A
24 total of 669,922 children were included in the analysis.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Data on SSRIs use**

44
45 Information on SSRIs use was drawn from the Danish National Prescription Registry
46 (DNPR)³⁷. Since 1995, this registry has recorded all redeemed prescriptions in
47 Denmark with the following information: the civil registration number of the patient,
48 the dispensing date, the medication code (the WHO Anatomical Therapeutic Chemical
49 (ATC) classification system), the number of packages prescribed, and the number of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 doses units in package. Selective serotonin reuptake inhibitors use was identified
4 based on ATC codes: fluoxetine (N06AB03), citalopram (N06AB04), paroxetine
5 (N06AB05), sertraline (N06AB06), fluvoxamine (N06AB08), and escitalopram
6 (N06AB10). It is estimated that spermatogenesis takes approximately 74 days³⁰,
7 therefore we chose the last 3 months prior to conception as the exposure window to
8 cover the susceptible time period. A child was considered exposed if the dispensing
9 date fell within the specified exposure window or the number of days for which the
10 SSRIs medication was supplied overlapped any portion of the exposure window.
11 Children born to fathers who had no prescriptions for SSRIs and no supply overlap
12 during the entire exposure window were considered unexposed. The date of
13 conception was estimated by subtracting gestational age from the date of delivery.
14 Data on paternal SSRIs use during the last two years prior to the conception were
15 extracted for further analyses. We also retrieved the information about maternal SSRIs
16 use during the pregnancy.

17 **Autism spectrum disorders**

18 Autism spectrum disorders in children were identified by using the Danish Psychiatric
19 Central Research Register (DPCRR) and the Danish National Patient Register
20 (DNPR). The DPCRR contains diagnostic information on every admission from
21 psychiatric hospitals and psychiatric wards in general hospitals in Denmark since
22 1969, and includes data on all outpatient visits and emergency room contacts since
23 1995³⁸. The DNPR has collected data on all inpatients from all somatic hospitals in
24 Denmark since 1977 and outpatients from 1995³⁹. The combined data from the two

registries were used to identify all children diagnosed with ASD. During the study period, the diagnosis of ASD was based on the International Classification of Diseases, 10th version (ICD-10) codes of F84.0 (Childhood autism), F84.1 (Atypical autism), F84.5 (Asperger syndrome), F84.8 (other pervasive developmental disorders) and F84.9 (unspecified pervasive developmental disorders). The quality of the childhood autism diagnosis has been validated and the diagnoses could be verified in 94% of the children with a record in the DPCRR⁴⁰. Children were followed up from birth till first diagnosis of ASD, death, emigration, or December 31, 2013, whichever came first.

Covariates

Using the Danish nationwide health registers, we retrieved data on characteristics that may be associated with offspring ASD or paternal SSRIs use. For each child, we obtained information on calendar year of birth, gender of the child, birth weight, Apgar score at 5 minutes, gestational age, maternal parity, maternal age at child birth, paternal age at child birth and maternal smoking status during pregnancy from the DMBR. Parents' psychiatric history prior to birth of the index child was obtained from DPCRR by ICD-8 codes 290-315 from 1977 to 1993 and ICD-10 codes F00-F99 from 1994 onward. Furthermore, we identified parents diagnosed with affective disorders before birth of child (specifically, ICD-8 codes 296.09, 296.19, 296.29, 296.39, 296.99, 298.09, 298.19, 300.49, and 301.19, and ICD-10 codes F30–F34 and F38–F39) using the DPCRR.

Statistical Analysis

1
2
3
4 Cox proportional-hazards regression models were used to estimate the hazard ratios
5
6 (HRs) and 95% confidence intervals (CIs) of ASD in children following exposure to
7
8 paternal SSRIs use before conception.
9

10
11 We adjusted for variables as following: the calendar year of birth (1998-2000,
12
13 2001-2003, 2004-2006, 2007-2008), gender of the child (boy, girl), parity (1, 2, ≥ 3),
14
15 parental age at child birth (≤ 25 , 26-30, 31-35, and > 35 years), maternal smoking
16
17 status during pregnancy (yes or no), maternal history of psychiatric disorders before
18
19 birth of child (yes or no), maternal antidepressants use during pregnancy (yes or no)
20
21 in model 1. We additionally adjusted for paternal history of psychiatric disorders
22
23 before birth of child (yes or no) in model 2. Models were also run with the exclusion
24
25 of those children with missing data for covariates.
26
27
28
29

30
31 To distinguish the direct effects of SSRIs use from the effects of the indication of
32
33 SSRIs use, we extended the exposure window to 1 year before conception. We then
34
35 re-categorized the exposed children into three subgroups: children of fathers who used
36
37 SSRIs 1) only from the last year till the last 3 months prior to conception (former
38
39 users); 2) only during the last 3 months prior to conception (current short-term users,
40
41 hereinafter referred to as 'current users'); 3) both before and during the last 3 months
42
43 prior to conception (both former and current users). The reference group consisted of
44
45 those children born to fathers who never used SSRIs medication through the last year
46
47 before conception.
48
49
50
51

52
53 The stratified analysis was performed to examine whether the association between
54
55 paternal SSRIs use and ASD in children differed by gender. We also restricted the
56
57
58
59

1
2
3 analyses to children whose mothers neither received antidepressant medication during
4 pregnancy nor had affective disorder before birth of child. To further distinguish the
5 effect of SSRIs medication from that of the main indication (i.e., affective disorders)
6 for SSRIs treatment, we performed stratified analyses according to paternal history of
7 affective disorder before birth of the index child. As for those children born to fathers
8 with affective disorders, the ASD risk we examined could be solely attributable to
9 paternal SSRIs use since both of the exposed children and the reference children were
10 with paternal affective disorders.
11
12
13
14
15
16
17
18
19
20
21
22

23 Besides, to control for unmeasured family-related confounding factors, we
24 re-conducted a sibling study by restricting to families with more than one child and
25 with at least one child with paternal SSRIs preconception exposure. Using the
26 stratified Cox proportional-hazards regression, we then compared exposed siblings to
27 unexposed siblings to estimate the association between paternal SSRIs use before
28 conception and ASD in children.
29
30
31
32
33
34
35
36

37 All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary,
38 North Carolina, USA).
39
40
41

42 **Results**

43
44 Among the 669,922 singletons included in the study, 6,870 (1.03%) children were
45 born to fathers who had redeemed a prescription for SSRIs during the last 3 months
46 prior to conception. During the study period, a total of 7,577 children were diagnosed
47 with ASD. The median age at diagnosis of ASD was 6.77 years (interquartile range:
48 4.84 to 9.48 years). Characteristics of the study population are shown in Table 1.
49
50
51
52
53
54
55
56

1
2
3 Compared with the unexposed group, there were a higher proportion of exposed
4 children born in later calendar years. Fathers in exposed group were more likely to be
5
6 older at child birth and to have a history of psychiatric disorder (including affective
7
8 disorder) before birth of child. Mothers of exposed children were characterized as
9
10 having higher parity, being more likely to be older at child birth, to use
11
12 antidepressants during pregnancy, and to have a history of psychiatric disorder before
13
14 birth of child.
15
16
17
18
19

20
21 Among 61,555 person-years of follow-up, we identified 104 cases of ASD in
22
23 children born to fathers who used SSRIs during the last 3 months prior to conception
24
25 (incidence rate: 169 per 100,000 person-years). This incidence rate corresponded to a
26
27 62% increased risk of ASD compared with the unexposed group (Table 2). The
28
29 adjusted HR (aHR) of ASD was 1.54 (95% CI: 1.27-1.88) after adjusting for potential
30
31 confounders in model 1. After paternal psychiatric history was further adjusted for in
32
33 model 2, the estimate was 1.43 (95%CI: 1.18-1.74). When extending the exposure
34
35 window to the last one year prior to conception, after the full adjustment, the HR for
36
37 ASD in children of fathers who were former users only and who were both former
38
39 and current users was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72),
40
41
42 respectively. However, the increased risk decreased and became nonsignificant among
43
44 children of fathers who were only current users (aHR=1.17, 95%CI: 0.75-1.82, model
45
46
47
48
49 2, table2).
50
51

52 The risk estimates of ASD were similar for both boys and girls, regardless of the
53
54 exposure (Table S1). When we restricted analyses to children whose mothers neither
55
56
57
58
59

1
2
3 used SSRIs during pregnancy nor had affective disorder before birth of child, the
4
5
6 results did not change essentially (Table S2).
7

8
9 When the analyses were stratified by paternal affective disorder before birth of the
10
11 index child, in children born to fathers with a history of affective disorder, there was
12
13 no association between paternal SSRIs use before conception and ASD in the
14
15 offspring (model 2: aHR=1.10, 95%CI: 0.61-1.98). For children whose father without
16
17 affective disorder, the patterns of associations remained similar to those of the main
18
19 analyses (Table 3).
20
21

22
23 In the sibling analysis, we identified 5,479 families with more than one child and
24
25 with at least one child with paternal SSRIs use before conception (Table 4). The risk
26
27 of ASD in exposed children was similar when compared with their unexposed siblings
28
29 (aHR=1.04, 95%CI: 0.94-1.14).
30
31

32 33 **Discussion**

34
35 In this large population-based cohort study, we observed an increased risk of ASD in
36
37 the offspring following paternal use of SSRIs during the last 3 months prior to
38
39 conception. However, the risk attenuated after adjusting for a number of potential
40
41 confounders, especially fathers' psychiatric conditions. When extending the exposure
42
43 window to one year before conception, the ASD risk persisted among children born to
44
45 former users but not current users. In addition, among children born to father with
46
47 affective disorder, no association was observed. Finally, we performed a sibling
48
49 analysis which allowed for better control of unmeasured familial confounding and no
50
51 difference in the ASD risk was found among exposed children and their unexposed
52
53
54
55
56
57
58
59
60

1
2
3 siblings. Taken as a whole, our results did not support that paternal SSRIs use before
4
5
6 conception could increase the risk of ASD in children.
7

8
9
10 Recently, concerns have been raised regarding the risk of ASD in the offspring
11 associated with prenatal exposure to SSRIs. Three previous human studies have
12 suggested that in utero exposure to antidepressants would increase the risk of ASD in
13 children²¹⁻²³, although another two studies using the Danish registers have reported no
14
15 significant association^{41,42}. Basic neuro-biologic studies have showed that prenatal
16
17 SSRIs administration may be part of a causal pathway to ASD by operating directly
18
19 on the developing brain^{43,44}. Considering the detrimental effect of SSRIs on sperm^{32,}
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Recently, concerns have been raised regarding the risk of ASD in the offspring associated with prenatal exposure to SSRIs. Three previous human studies have suggested that in utero exposure to antidepressants would increase the risk of ASD in children²¹⁻²³, although another two studies using the Danish registers have reported no significant association^{41,42}. Basic neuro-biologic studies have showed that prenatal SSRIs administration may be part of a causal pathway to ASD by operating directly on the developing brain^{43,44}. Considering the detrimental effect of SSRIs on sperm^{32, 33, 45}, paternal SSRIs use before conception may also cause adverse effects on pregnancy outcomes. However, till now, only one study have suggested that SSRIs administration to male rats could induce deterioration in fertility and fetal outcomes (including weight gain, organ weights and feed consumption)⁴⁶. To our knowledge, our study is the first to investigate the link between paternal antidepressants use and ASD risk in children. Considering the limited number of ASD cases and the challenges posed by confounding, further studies are needed to corroborate the findings.

In the present study, the increased risk of ASD observed in former users but not in current users implied that indications for paternal SSRIs use may account for the observed association between paternal SSRIs use and ASD in children, which was supported by previous studies suggesting that parental depression and other psychiatric disorders might be associated with the risk of autism in children⁴⁷⁻⁴⁹. In

1
2
3 children born to fathers without affective disorders, there was an increased risk
4
5 associated with paternal SSRIs use. Most fathers might receive SSRIs treatment from
6
7 their general practitioner and were therefore not registered with a diagnosis of
8
9 affective disorders in the hospital system. Therefore, it was possible that the increased
10
11 risk associated with prenatal SSRIs use was partly confounded by paternal affective
12
13 disorders diagnosed outside a hospital department for which we were not able to
14
15 adjust. In addition, other psychiatric diseases related to SSRIs use might also
16
17 contribute to the observed association.
18
19
20
21
22

23 Our study has several methodological strengths. One strength was that the linkage
24
25 of several nationwide health registries in Denmark enabled us to conduct a large
26
27 cohort study with virtually complete follow-up. The definition on exposure to SSRIs
28
29 was based on a national registry, which eliminated the risk of recall bias caused by
30
31 self-report. Another strength was that the information on ASD diagnosis was obtained
32
33 independently of exposure measurement, which could also mitigate the information
34
35 bias. Furthermore, the availability of health registry data enabled us to adjust for a
36
37 number of potential confounders including sociodemographic factors as well as
38
39 parental psychiatric history.
40
41
42
43
44

45 Limitations need to be considered when interpreting the results of our study.
46
47 Firstly, we were unable to validate actual use of SSRIs by fathers during the time
48
49 period of interest because we relied on medical records of dispensed prescriptions.
50
51 This may lead to misclassification of exposure status because some people may not
52
53 take the medication or may take it later. Nevertheless, the misclassification was most
54
55
56
57
58
59
60

1
2
3 likely non-differential, which could bias the association toward null. Besides, some
4
5 patients may receive SSRIs treatment during inpatient admissions which are not
6
7 included in the prescription registry. We expect this problem to be minor since those
8
9 inpatients usually have severe psychiatric disorders and are more likely to continue
10
11 treatment after discharge. Secondly, the 3-month cut-off point was set based on the
12
13 fact that spermatogenesis takes approximately 70-90 days in humans. Whereas it may
14
15 be possible that SSRIs drugs induce sperm damage at the very primitive stage.
16
17 However, the results did not change markedly after extending the putative exposure
18
19 period to the last 6 months prior to conception (data not shown). Thirdly, ASD in
20
21 children was ascertained through the DNPR and the DPCRR, which did not include
22
23 those children who received the diagnosis of ASD from private psychiatrists or
24
25 remained undiagnosed at the end of the follow-up. However, the prevalence of ASD
26
27 in our cohort was 1.13%, which was similar to that reported in the United States
28
29 during the study period (1.14%)⁵⁰. Hence the bias introduced by case identification
30
31 was expected to be minimal.
32
33
34
35
36
37
38
39

40 **Conclusions**

41
42 In the study, paternal SSRI use before conception was associated with an increased
43
44 risk of ASD in the offspring, especially in the former users who took SSRIs over the
45
46 longer term. However, null association were observed in exposed children with
47
48 paternal affective disorders, and similar ASD risk were observed among exposed and
49
50 unexposed siblings, which implicates that paternal underlying indications related to
51
52 SSRIs use or other unmeasured confounding factors may explain the increased risk.
53
54
55
56
57
58
59
60

Footnotes

This cohort study was approved by the Danish Data Protection Agency (Document No. 2013-41-2569).

Contributors: HL had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. HL, WY and JL conceptualized and designed the study. FY conducted the statistical analysis. HL, PC and FY interpreted the results and FY drafted the initial manuscript. All authors reviewed the manuscript and approved the final version.

Funding: The study was supported by the National Natural Science Foundation of China (81428011), the National Key Research and Development Program of China (2016YFC1000505), the European Research Council (ERC-2010-StG-260242-PROGEURO), Nordic Cancer Union (176673,186200), Danish Council for Independent Research (DFR-6110-00019), Karen Elise Jensens Fond (2016), and the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation.

Competing interests: The authors declare that they have no conflict of interest.

Statement of the independence of researchers from funders: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The researchers were independent from the funders.

Ethical approval: The study was based on secondary data. No individuals were approached as a result of the study, nor did we access any other data from the

1
2
3 participants. This study was approved by the Danish Data Protection Agency
4
5
6 (Document No. 2013-41-2569). All procedures performed in the study involving
7
8 human participants were in accordance with the ethical standards of the institutional
9
10 and/or national research committee and with the 1964 Helsinki declaration and its
11
12 later amendments or comparable ethical standards. For this type of study formal
13
14 consent is not required.
15
16

17
18 **Data sharing statement:** No additional data are available.
19

20 21 Reference

- 22 1. Organization WH. Depression [fact sheet no. 369]. 2012. As of September. 2015;30.
- 23 2. Alwan S, Friedman JM, Chambers C. Safety of selective serotonin reuptake inhibitors in
24 pregnancy: a review of current evidence. *CNS drugs*. 2016;30(6):499-515.
- 25 3. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy
26 outcomes. *American journal of obstetrics and gynecology*. 2006;194(4):961-966.
- 27 4. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and
28 pregnancy outcomes. *Archives of pediatrics & adolescent medicine*. 2009;163(10):949-954.
- 29 5. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in
30 pregnancy and congenital malformations: population based cohort study. *Bmj*. 2009;339:b3569.
- 31 6. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of
32 depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during
33 pregnancy. *Archives of pediatrics & adolescent medicine*. 2007;161(1):22-29.
- 34 7. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to
35 venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *American
36 Journal of Psychiatry*. 2012;169(11):1165-1174.
- 37 8. Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy
38 and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and
39 physiological evidence. *International Journal of Risk & Safety in Medicine*. 2016;28(3):125-141.
- 40 9. Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated
41 with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health
42 system. *Molecular psychiatry*. 2015;20(6):727-734.
- 43 10. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of
44 autism spectrum disorder in children. *JAMA pediatrics*. 2016;170(2):117-124.
- 45 11. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link? *Medical
46 Hypotheses*. 2010;74(5):880-883.
- 47 12. Brown HK, Ray JG, Wilton AS, et al. Association Between Serotonergic Antidepressant Use During
48 Pregnancy and Autism Spectrum Disorder in Children. *Jama*. 2017;317(15):1544-1552.
- 49 13. Sujan AC, Rickert ME, Öberg AS, et al. Associations of Maternal Antidepressant Use During the
50
51
52
53
54
55
56
57

1
2
3 First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
4 and Attention-Deficit/Hyperactivity Disorder in Offspring. *Jama*. 2017;317(15):1553-1562.

5 14. Oberlander TF, Zwaigenbaum L. Disentangling Maternal Depression and Antidepressant Use
6 During Pregnancy as Risks for Autism in Children. *Jama*. 2017;317(15):1533-1534.

7 15. Mezzacappa A, Lasica P-A, Gianfagna F, et al. Risk for Autism Spectrum Disorders According to
8 Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis. *JAMA pediatrics*.
9 2017.

10 16. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a
11 population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *The*
12 *lancet*. 2006;368(9531):210-215.

13 17. Rutter M. Incidence of autism spectrum disorders: Changes over time and their meaning*. *Acta*
14 *paediatrica*. 2005;94(1):2-15.

15 18. Hill AP, Zuckerman K, Fombonne E. Epidemiology of autism spectrum disorders. *Translational*
16 *Approaches to Autism Spectrum Disorder*: Springer 2015:13-38.

17 19. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders*.
18 *Annu Rev Public Health*. 2007;28:235-258.

19 20. Brown HK, Hussain-Shamsy N, Lunskey Y, et al. The association between antenatal exposure to
20 selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. *The Journal*
21 *of clinical psychiatry*. 2017;78(1):e48.

22 21. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors
23 and risk for autism spectrum disorder. *Journal of autism and developmental disorders*.
24 2014;44(10):2558-2567.

25 22. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood
26 autism spectrum disorders. *Archives of general psychiatry*. 2011;68(11):1104-1112.

27 23. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during
28 pregnancy, and risk of autism spectrum disorders: population based case-control study. 2013.

29 24. Schirm E, Pedersen L, Tobi H, et al. Drug use among fathers around time of conception: two
30 register based surveys from Denmark and The Netherlands. *Pharmacoepidemiology and drug safety*.
31 2004;13(9):609-613.

32 25. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers
33 before and during pregnancy. A population - based cohort study of 106 000 pregnancies in Norway
34 2004–2006. *British journal of clinical pharmacology*. 2008;65(5):653-660.

35 26. Crijns I, Bos J, Knol M, et al. Paternal drug use: before and during pregnancy. *Expert opinion on*
36 *drug safety*. 2012;11(4):513-518.

37 27. Sever LE. Male-mediated developmental toxicity. *Toxicology & Applied Pharmacology*.
38 1993;14(1):506–513.

39 28. Friedler G. Paternal exposures: Impact on reproductive and developmental outcome. An
40 overview. *Pharmacology Biochemistry & Behavior*. 1996;55(4):691-700.

41 29. Anderson D, Schmid TE, Baumgartner A. Male-mediated developmental toxicity. *Asian journal of*
42 *andrology*. 2014;16(1):81.

43 30. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. *Basic & clinical*
44 *pharmacology & toxicology*. 2008;102(2):176-181.

45 31. Engeland A, Børge T, Daltveit AK, et al. Effects of preconceptional paternal drug exposure on
46 birth outcomes: cohort study of 340 000 pregnancies using Norwegian population - based databases.

- 1
2
3 British journal of clinical pharmacology. 2013;75(4):1134-1141.
- 4 32. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. Fertility and
5 sterility. 2010;94(3):1021-1026.
- 6 33. Safarinejad MR. Sperm DNA damage and semen quality impairment after treatment with
7 selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure
8 assay. The Journal of urology. 2008;180(5):2124-2128.
- 9 34. Lewis S, Aitken R. DNA damage to spermatozoa has impacts on fertilization and pregnancy. Cell
10 and tissue research. 2005;322(1):33-41.
- 11 35. Pedersen CB, Gøtzsche H, Møller JØ, et al. The Danish civil registration system. Dan Med Bull.
12 2006;53(4):441-449.
- 13 36. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Danish medical bulletin.
14 1998;45(3):320-323.
- 15 37. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scandinavian
16 journal of public health. 2011;39(7 suppl):38-41.
- 17 38. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. Scandinavian
18 journal of public health. 2011;39(7 suppl):54-57.
- 19 39. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable
20 source of data for modern health sciences. Danish medical bulletin. 1999;46(3):263-268.
- 21 40. Lauritsen MB, Jørgensen M, Madsen KM, et al. Validity of childhood autism in the Danish
22 Psychiatric Central Register: findings from a cohort sample born 1990–1999. Journal of autism and
23 developmental disorders. 2010;40(2):139-148.
- 24 41. Christensen J, Parner ET, Vestergaard M. Antidepressant exposure in pregnancy and risk of autism
25 spectrum disorders. Clinical epidemiology. 2013;5:449-459.
- 26 42. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy
27 and risk of autism. New England Journal of Medicine. 2013;369(25):2406-2415.
- 28 43. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects
29 on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31(1):47-57.
- 30 44. Bonnin A, Levitt P. Fetal, maternal and placental sources of serotonin and new implications for
31 developmental programming of the brain. Neuroscience. 2011;197:1.
- 32 45. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. Urology.
33 2007;69(1):185. e185-185. e187.
- 34 46. Elmazoudy R, Abdelhameed N, Elmasry A. Paternal dapoxetine administration induced
35 deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male
36 rats. International Journal of Impotence Research. 2015;27(6).
- 37 47. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism
38 spectrum disorders in the offspring. Pediatrics. 2008;121(5):e1357-e1362.
- 39 48. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, parental
40 psychiatric history, and socioeconomic status. American journal of epidemiology.
41 2005;161(10):916-925.
- 42 49. Jokiranta E, Brown AS, Heinimaa M, et al. Parental psychiatric disorders and autism spectrum
43 disorders. Psychiatry research. 2013;207(3):203-211.
- 44 50. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism
45 spectrum disorder among children in the US, 2007. Pediatrics. 2009;124(5):1395-1403.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline Characteristics of the study population

Characteristic	Paternal SSRIs use during the last 3 months prior to conception (N=6,870)	No paternal SSRIs use during the last 3 months prior to conception (N=663, 052)
Calendar Year of birth, No. (%)		
1998-2000	1,021(14.9)	185,784(28.0)
2001-2003	1,526(22.2)	179,952(27.1)
2004-2006	2,305(33.5)	178,664(27.0)
2007-2008	2,018(29.4)	118,652(17.9)
Gender, No. (%)		
Boy	3,549(51.7)	340,194(51.3)
Girl	3,321(48.3)	322,858(48.7)
Birth Weight (g), No. (%)		
<2500	278(4.1)	22,315(3.4)
2500-3250	1,729(25.2)	154,494(23.3)
3250-4000	3,582(52.1)	348,853(52.6)
4000-8000	1,243(18.1)	132,343(19.9)
Unknown	38(0.5)	5,047(0.8)
Parity, No. (%)		
1	2,693(39.2)	282,895(42.7)
2	2,433(35.4)	250,496(37.8)
≥3	1,744(25.4)	129,661(19.5)
Preterm Birth, No. (%) (<37 weeks)		
No	6,489(94.4)	630,851(95.1)
Yes	381(5.6)	32,201(4.9)
Apgar score at 5 minutes, No. (%)		
0-7	91(1.3)	8,224(1.2)
8-9	442(6.4)	39,941(6.0)
10	6,269(91.3)	607,634(91.7)
Unknown	68(1.0)	7,253(1.1)
Maternal age at child birth (years), No. (%)		
≤25	958(13.9)	99,273(15.0)
26-30	2,238(32.6)	244,419(36.9)
31-35	2,386(34.7)	225,610(34.0)
>35	1,288(18.8)	93,750(14.1)
Paternal age at child birth (years), No. (%)		
≤25	364(5.3)	47,490(7.2)
26-30	1,434(20.9)	180,612(27.2)
31-35	2,395(34.8)	242,702(36.6)
>35	2,677(39.0)	192,248(29.0)

Table 1. Baseline Characteristics of the study population (continued)

Maternal smoking status^a, No. (%)		
No	4,326(63.0)	477,574(72.0)
Yes	1,334(19.4)	106,233(16.0)
Unknown	1,210(17.6)	79,245(12.0)
Maternal AD use during pregnancy, No. (%)		
No	6,548(94.0)	653,496(98.6)
Yes	412(6.0)	9,556(1.4)
Maternal history of Affective disorder, No. (%)		
No	6,607(96.2)	654,234(98.7)
Yes	263(3.8)	8,818(1.3)
Paternal history of Affective disorder, No. (%)		
No	6,099 (88.8)	659,639(99.5)
Yes	771(11.2)	3,413(0.5)
Maternal history of psychiatric disorder, No. (%)		
No	6,175(89.9)	626,840(94.5)
Yes	695(10.1)	36,212(5.5)
Paternal history of psychiatric disorder, No. (%)		
No	5,092 (74.1)	630,990(95.2)
Yes	1,178(25.9)	32,062(4.8)

Abbreviations: SSRI, selective serotonin reuptake inhibitor; N, number; AD, antidepressant drugs;

^a Maternal smoking information was missing among those children born from 2007 to 2008.

Table 2. Association between paternal SSRIs use before conception and ASD in offspring

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,473	6,765,205	Ref	Ref	Ref
Use during the last 3 months prior to conception	104	61,555	1.62(1.33-1.96)	1.54(1.27-1.88)	1.43(1.18-1.74)
No use during the last 1 year prior to conception	7,429	6,736,654	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	71	39,422	1.71(1.35-2.16)	1.66(1.31-2.09)	1.54(1.21-1.94)
Use only during the last 3 months prior to conception	20	14,738	1.29(0.83-2.00)	1.24 (0.80-1.93)	1.17(0.75-1.82)
Use both before and during the last 3 months prior to conception	57	35,946	1.52(1.17-1.97)	1.43(1.10-1.86)	1.32(1.02-1.72)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 3. Association between paternal SSRIs use before conception and ASD in offspring born to fathers diagnosed with affective disorder or not

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Fathers with affective disorder					
No use during the last 3 months prior to conception	58	30,908	Ref	Ref	Ref
Use during the last 3 months prior to conception	14	6,625	1.17(0.65-2.09)	1.10(0.61-1.98)	1.10(0.61-1.98)
No use during the last 1 year prior to conception	53	28,033	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	8	4,082	1.07(0.51-2.25)	1.08(0.51-2.30)	1.08(0.51-2.30)
Use only during the last 3 months prior to conception	2	1,164	0.91(0.22-3.75)	0.89(0.21-3.75)	0.89(0.21-3.75)
Use both before and during the last 3 months prior to conception	9	4,254	1.16(0.57-2.35)	1.10(0.55-2.22)	1.10(0.55-2.22)
Fathers without affective disorder					
No use during the last 3 months prior to conception	7,415	6,752,899	Ref	Ref	Ref
Use during the last 3 months prior to conception	90	36,329	1.57(1.27-1.93)	1.52(1.23-1.87)	1.45(1.18-1.79)
No use during the last 1 year prior to conception	7,376	6,714,926	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	63	37,973	1.69(1.32-2.17)	1.64(1.28-2.11)	1.57(1.23-2.02)
Use only during the last 3 months prior to conception	18	7,354	1.26(0.79-2.00)	1.23(0.77-1.95)	1.19(0.75-1.88)
Use both before and during the last 3 months prior to conception	48	28,974	1.45(1.09-1.93)	1.38(1.04-1.84)	1.32(0.99-1.76)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 4. Paternal SSRI use before pregnancy and ASD in exposed and unexposed siblings from 5,479 families

Paternal SSRIs use before conception	Number of offspring no.	Offspring with ASD no.	Hazard Ratio (95% CI)	
			Crude	Model 1 ^a
No use during the last 3 months prior to conception	2,792	45	Ref	Ref
Use during the last 3 months prior to conception	2,687	23	1.08(1.01-1.16)	1.04(0.94-1.14)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for sex, parity, mother age, father age, maternal smoking, maternal AD use during pregnancy

TablesS1. Association between paternal SSRIs use before conception and ASD in offspring: analyses stratified by gender

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Boys					
No use during the last 3 months prior to conception	6,005	3,459,592	Ref	Ref	Ref
Use during the last 3 months prior to conception	84	31,642	1.61(1.30-2.00)	1.55(1.25-1.92)	1.44(1.16-1.79)
No use during the last 1 year prior to conception	5,969	3,444,956	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	58	20,031	1.74(1.34-2.25)	1.69(1.30-2.19)	1.58(1.22-2.05)
Use only during the last 3 months prior to conception	18	7,622	1.42(0.89-2.26)	1.39(0.87-2.21)	1.31(0.83-2.09)
Use both before and during the last 3 months prior to conception	44	18,623	1.44 (1.07-1.93)	1.36(1.01-1.84)	1.26(0.94-1.71)
Girls					
No use during the last 3 months prior to conception	1,468	3,305,613	Ref	Ref	Ref
Use during the last 3 months prior to conception	20	29,914	1.63(1.05-2.53)	1.54(0.99-2.40)	1.41(0.90-2.20)
No use during the last 1 year prior to conception	1,460	3,291,698	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	13	19,390	1.61(0.93-2.78)	1.53(0.88-2.64)	1.37(0.79-2.38)
Use only during the last 3 months prior to conception	2	7,116	0.67(0.17-2.69)	0.64(0.16-2.55)	0.59(0.15-2.36)
Use both before and during the last 3 months prior to conception	13	75,323	1.84(1.06-3.17)	1.74(1.01-3.01)	1.59(0.92-2.75)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

TableS2. Association between paternal SSRIs use before conception and ASD in offspring born to mother who neither received antidepressants medication during pregnancy nor had affective disorders before birth of child

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,184	6,627,720	Ref	Ref	Ref
Use during the last 3 months prior to conception	91	57,081	1.55(1.26-1.91)	1.57(1.28-1.93)	1.45(1.18-1.79)
No use during the last 1 year prior to conception	7,144	6,600,852	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	64	37,032	1.67(1.30-2.13)	1.68(1.31-2.15)	1.56(1.22-1.99)
Use only during the last 3 months prior to conception	16	13,634	1.13(0.69-1.85)	1.15(0.71-1.89)	1.08(0.66-1.77)
Use both before and during the last 3 months prior to conception	51	33,283	1.50(1.13-1.97)	1.50(1.13-1.97)	1.38(1.05-1.82)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history

^b Model 1 further adjusted for father psychiatric history

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	9

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	20
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-11
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	19
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016368.R2
Article Type:	Research
Date Submitted by the Author:	13-Oct-2017
Complete List of Authors:	<p>Yang, Fen; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science; Aarhus Universitetshospital, Department of Clinical Epidemiology</p> <p>Chen, Jianping; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science</p> <p>Miao, Mao-Hua; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Yuan, Wei; Shanghai Institute of Planned Parenthood Research, Reproductive Epidemiology, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Li, Lin; Shanghai Institute of Planned Parenthood Research</p> <p>Liang, Hong; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Ehrenstein, Vera; Aarhus Universitetshospital</p> <p>Li, Jiong; Aarhus Universitetshospital, Department of Clinical Epidemiology</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Mental health
Keywords:	MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, NEUROPATHOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Risk of autism spectrum disorder in offspring following paternal use of selective**
4 **serotonin reuptake inhibitors before conception: a population-based cohort**
5 **study**
6
7
8
9

10 Fen Yang^{1,2}; Jianping Chen¹; Maohua Miao¹; Wei Yuan¹; Lin Li¹; Hong Liang¹; Vera
11 Ehrenstein²; Jiong Li²
12
13
14
15

16
17
18 **Author Affiliation**
19

20 ¹Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
21 Shanghai, 200032, China
22
23

24 ²Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle
25 43-45, DK-8200 Aarhus N, Denmark
26
27
28
29

30
31
32
33 **Corresponding Author**
34

35 Hong Liang, MD, PhD
36

37 Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
38 #779 Lao Hu Min Road, Shanghai, 200032, China.
39
40

41 Email: lucylhcn@163.com;
42

43 Phone number: 86 -21-64771683
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective

The present study aimed to examine the association between paternal selective serotonin reuptake inhibitors (SSRIs) use before conception and the risk of autism spectrum disorder (ASD) in offspring.

Design

A population-based cohort study

Methods

Based on Danish national registers, we conducted a cohort study of 669,922 children born from 1998 to 2008, with follow-up throughout 2013. The children whose fathers used SSRIs during the last 3 months prior to conception were identified as the exposed. Cox regression model was used to estimate the hazard ratio (HR) for ASD in children.

Results

Compared with unexposed children, the exposed had a 1.43-fold higher risk of ASD (HR=1.43, 95% confidence interval [CI]: 1.18-1.74) after adjusting for potential confounders. When extending the exposure window to 1 year before conception, the adjusted HR (aHR) of ASD in children of fathers who used SSRIs only from the last year till the last 3 months prior to conception and who used SSRIs both before and during the last 3 months prior to conception was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72), respectively. Whereas, the risk in children of fathers who used SSRIs only during the last 3 months prior to conception decreased and became

nonsignificant (aHR=1.17, 95%CI: 0.75-1.82).

Conclusions

The increased risk of ASD in the offspring associated with paternal SSRIs use before conception may be attributable to the underlying indications.

Strengths and limitations of this study

- This is the very first study that investigates the link between paternal antidepressants use and ASD risk in children.
- A number of potential confounders, including sociodemographic factors as well as parental psychiatric history, can be adjusted for based on the availability of national health registry data.
- Actual use of SSRIs by fathers during the time period of interest may not be validated.
- Those children who received the diagnosis of ASD from private psychiatrists or remained undiagnosed at the end of the follow-up may not be identified as ASD case.

Introduction

Depression is a common mental health problem that affects approximately 350 million people worldwide¹. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and other anxiety-related disorders. However, an increasing body of evidence suggests that prenatal exposure to SSRIs is associated with adverse obstetrical and neonatal outcomes²⁻⁵. In addition, recent studies have indicated a possible link between prenatal SSRI exposure and neurobehavioral problems in children^{2, 6-10}, which may be due to the biological mechanisms (i.e. dysfunctional serotonin signaling)¹¹. Whereas several studies have suggested that the previously observed association between prenatal SSRI exposure and neurodevelopmental diseases might be due to confounding by related indications¹²⁻¹⁵.

Autism spectrum disorder (ASD) is one of the major neurodevelopmental disorders characterized by impairments in reciprocal social interaction, communication, and repetitive or stereotypic behavior¹⁶. The estimated prevalence of ASD has dramatically increased from less than 1 in 2,000 children in the 1960s to approximately 1 in 145 children today^{17, 18}. Both genetic and environmental risk factors may contribute to ASD¹⁹. Recently, maternal use of SSRIs during pregnancy has been reported to be associated with an increased risk of ASD in children^{10, 20-24}.

If maternal SSRI exposure during pregnancy plays a role in fetal, even in child's, development, an extended effect of earlier exposure on gamete, particularly human sperm, is biologically plausible. Therefore, the potential role of paternal SSRI use in

1
2
3 ASD should also be taken into consideration. Studies in the Nordic countries show
4
5 that one-third of the fathers used prescription drugs during the last 6 months prior to
6
7 conception²⁵, and approximately 1.4% of fathers were dispensed SSRIs during the
8
9 last 3 months prior to conception^{26, 27}. Although the information regarding the
10
11 potential effects of SSRI use by fathers is limited, the hypothesis of an increased risk
12
13 of adverse pregnancy or neonatal outcome associated with paternal drug exposure is
14
15 not new. Several human studies have indicated the adverse effects of paternal SSRIs
16
17 use, including impaired semen quality and abnormal sperm DNA fragmentation,
18
19 which has been reported to be associated with diminished fertility, adverse pregnancy
20
21 outcomes (like pregnancy loss), and an increased risk of childhood disease²⁸⁻³⁰.
22
23
24
25
26
27

28 Little is known on whether paternal SSRIs use before conception contributes to
29
30 the risk of ASD in offspring. We conducted a population-based cohort study to
31
32 examine the association between paternal SSRIs use during the last 3 months prior to
33
34 conception and risk of ASD in offspring, utilizing data from national Danish health
35
36 registries.
37
38
39

40 **Methods**

41 **Study Population**

42
43 This study was based on several national registers in Denmark. Each Danish resident
44
45 is assigned a unique personal identification number (a 10-digit civil registration
46
47 system number used in all registries), which enables accurate linkage of national
48
49 registries at the individual level³¹. The Danish Medical Birth Registry (DMBR)
50
51 contains records of all deliveries in Denmark since 1973 and includes information
52
53
54
55
56
57
58
59
60

1
2
3
4 about gestational age at birth from 1978³². Using the DMBR data, we identified a
5
6 cohort of all singletons born alive in Denmark during the period of January 1, 1998
7
8 through December 31, 2008 (n=687,580). We excluded children without linkage to
9
10 their father (n=16,955) or their mother (n=74), with missing parity (n=208), and with
11
12 missing or extreme values of gestational age (≤ 23 weeks or ≥ 45 weeks, n=421). A
13
14 total of 669,922 children were included in the analysis.
15
16

17 18 **Data on SSRIs use**

19
20 Information on SSRIs use was drawn from the Danish National Prescription Registry
21
22 (DNPR)³³. Since 1995, this registry has recorded all redeemed prescriptions in
23
24 Denmark with the following information: the civil registration number of the patient,
25
26 the dispensing date, the medication code (the WHO Anatomical Therapeutic Chemical
27
28 (ATC) classification system), the number of packages prescribed, and the number of
29
30 doses units in package. Selective serotonin reuptake inhibitors use was identified
31
32 based on ATC codes: fluoxetine (N06AB03), citalopram (N06AB04), paroxetine
33
34 (N06AB05), sertraline (N06AB06), fluvoxamine (N06AB08), and escitalopram
35
36 (N06AB10). It is estimated that spermatogenesis takes approximately 74 days³⁴,
37
38 therefore we chose the last 3 months prior to conception as the exposure window to
39
40 cover the susceptible time period. A child was considered exposed if the dispensing
41
42 date fell within the specified exposure window or the number of days for which the
43
44 SSRIs medication was supplied overlapped any portion of the exposure window.
45
46 Children born to fathers who had no prescriptions for SSRIs and no supply overlap
47
48 during the entire exposure window were considered unexposed. The date of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conception was estimated by subtracting gestational age from the date of delivery.
4
5
6 Data on paternal SSRIs use during the last two years prior to the conception were
7
8 extracted for further analyses. We also retrieved the information about maternal SSRIs
9
10 use during the pregnancy.
11
12

13 **Autism spectrum disorders**

14
15 Autism spectrum disorders in children were identified by using the Danish Psychiatric
16
17 Central Research Register (DPCRR) and the Danish National Patient Register
18
19 (DNPR). The DPCRR contains diagnostic information on every admission from
20
21 psychiatric hospitals and psychiatric wards in general hospitals in Denmark since
22
23 1969, and includes data on all outpatient visits and emergency room contacts since
24
25 1995³⁵. The DNPR has collected data on all inpatients from all somatic hospitals in
26
27 Denmark since 1977 and outpatients from 1995³⁶. The combined data from the two
28
29 registries were used to identify all children diagnosed with ASD. During the study
30
31 period, the diagnosis of ASD was based on the International Classification of
32
33 Diseases, 10th version (ICD-10) codes of F84.0 (Childhood autism), F84.1 (Atypical
34
35 autism), F84.5 (Asperger syndrome), F84.8 (other pervasive developmental
36
37 disorders) and F84.9 (unspecified pervasive developmental disorders). The quality of
38
39 the childhood autism diagnosis has been validated and the diagnoses could be
40
41 verified in 94% of the children with a record in the DPCRR³⁷. Children were
42
43 followed up from birth till first diagnosis of ASD, death, emigration, or December 31,
44
45 2013, whichever came first.
46
47
48
49
50
51
52
53

54 **Covariates**

Using the Danish nationwide health registers, we retrieved data on characteristics that may be associated with offspring ASD or paternal SSRIs use. For each child, we obtained information on calendar year of birth, gender of the child, birth weight, Apgar score at 5 minutes, gestational age, maternal parity, maternal age at child birth, paternal age at child birth and maternal smoking status during pregnancy from the DMBR. Parents' psychiatric history prior to birth of the index child was obtained from DPCRR by ICD-8 codes 290-315 from 1977 to 1993 and ICD-10 codes F00-F99 from 1994 onward. Furthermore, we identified parents diagnosed with affective disorders before birth of child (specifically, ICD-8 codes 296.09, 296.19, 296.29, 296.39, 296.99, 298.09, 298.19, 300.49, and 301.19, and ICD-10 codes F30-F34 and F38-F39) using the DPCRR.

Statistical Analysis

Cox proportional-hazards regression models (using child's calendar age in years as the underlying timescale) were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of ASD in children following exposure to paternal SSRIs use before conception. Observations were censored if the child died or emigrated before the end of follow-up.

We adjusted for variables as following: the calendar year of birth (1998-2000, 2001-2003, 2004-2006, 2007-2008), gender of the child (boy, girl), parity (1, 2, ≥ 3), parental age at child birth (≤ 25 , 26-30, 31-35, and > 35 years), maternal smoking status during pregnancy (yes or no), maternal history of psychiatric disorders before birth of child (yes or no), maternal antidepressants use during pregnancy (yes or no)

1
2
3 in model 1. We additionally adjusted for paternal history of psychiatric disorders
4 before birth of child (yes or no) in model 2. Models were also run with the exclusion
5
6 of those children with missing data for covariates. The proportional hazard
7
8 assumption was evaluated for all variables included in the adjusted model by
9
10 comparing estimated log-minus-log survival curves.
11
12
13
14

15
16 To distinguish the direct effects of SSRIs use from the effects of the indication of
17
18 SSRIs use, we extended the exposure window to 1 year before conception. We then
19
20 re-categorized the exposed children into three subgroups: children of fathers who used
21
22 SSRIs 1) only from the last year till the last 3 months prior to conception (former
23
24 users); 2) only during the last 3 months prior to conception (current short-term users,
25
26 hereinafter referred to as ‘current users’); 3) both before and during the last 3 months
27
28 prior to conception (both former and current users). The reference group consisted of
29
30 those children born to fathers who never used SSRIs medication through the last year
31
32 before conception.
33
34
35
36

37
38 The stratified analysis was performed to examine whether the association between
39
40 paternal SSRIs use and ASD in children differed by gender. We also restricted the
41
42 analyses to children whose mothers neither received antidepressant medication during
43
44 pregnancy nor had affective disorder before birth of child. To further distinguish the
45
46 effect of SSRIs medication from that of the main indication (i.e., affective disorders)
47
48 for SSRIs treatment, we performed stratified analyses according to paternal history of
49
50 affective disorder before birth of the index child. As for those children born to fathers
51
52 with affective disorders, the ASD risk we examined could be solely attributable to
53
54
55
56
57
58
59
60

1
2
3 paternal SSRIs use since both of the exposed children and the reference children were
4
5
6 with paternal affective disorders.
7

8 To control for unmeasured family-related confounding factors (such as genetic
9
10 liability for neuropsychiatric conditions and early postnatal environmental influences),
11
12 we conducted sibling-matched analyses by only including the families with
13
14 exposure-discordant siblings, in which there was at least one child with paternal
15
16 SSRIs preconception exposure and one child without exposure. Using the stratified
17
18 Cox proportional-hazards regression with a separate stratum for each family, we
19
20
21 estimated the association between paternal SSRIs use before conception and ASD in
22
23 matched sets of exposure-discordant siblings. In the stratified Cox regression model,
24
25
26 we also adjusted for those covariates that varied among siblings with the same father
27
28 (including parental age at conception, maternal parity, smoking, and maternal AD use
29
30 during pregnancy).
31
32
33
34

35 All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary,
36
37 North Carolina, USA).
38
39

40 **Results**

41
42 Among the 669,922 singletons included in the study, 6,870 (1.03%) children were
43
44 born to fathers who had redeemed a prescription for SSRIs during the last 3 months
45
46 prior to conception. During the study period, a total of 7,577 children were diagnosed
47
48 with ASD. The median age at diagnosis of ASD was 6.77 years (interquartile range:
49
50 4.84 to 9.48 years). Characteristics of the study population are shown in Table 1.
51
52
53 Compared with the unexposed group, there were a higher proportion of exposed
54
55
56
57
58
59
60

1
2
3 children born in later calendar years. Fathers in exposed group were more likely to be
4
5 older at child birth and to have a history of psychiatric disorder (including affective
6
7 disorder) before birth of child. Mothers of exposed children were characterized as
8
9 having higher parity, being more likely to be older at child birth, to use
10
11 antidepressants during pregnancy, and to have a history of psychiatric disorder before
12
13 birth of child.
14
15
16
17

18 Among 61,555 person-years of follow-up, we identified 104 cases of ASD in
19
20 children born to fathers who used SSRIs during the last 3 months prior to conception
21
22 (incidence rate: 169 per 100,000 person-years). This incidence rate corresponded to a
23
24 62% increased risk of ASD compared with the unexposed group (Table 2). The
25
26 adjusted HR (aHR) of ASD was 1.54 (95% CI: 1.27-1.88) after adjusting for potential
27
28 confounders in model 1. After paternal psychiatric history was further adjusted for in
29
30 model 2, the estimate was 1.43 (95%CI: 1.18-1.74). When extending the exposure
31
32 window to the last one year prior to conception, after the full adjustment, the HR for
33
34 ASD in children of fathers who were former users only and who were both former
35
36 and current users was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72),
37
38 respectively. However, the increased risk decreased and became nonsignificant among
39
40 children of fathers who were only current users (aHR=1.17, 95%CI: 0.75-1.82, model
41
42 2, table2).
43
44
45
46
47
48
49

50 The risk estimates of ASD were similar for both boys and girls, regardless of the
51
52 exposure (Table S1). When we restricted analyses to children whose mothers neither
53
54
55
56
57
58
59
60

1
2
3 used SSRIs during pregnancy nor had affective disorder before birth of child, the
4
5
6 results did not change essentially (Table S2).
7

8
9 When the analyses were stratified by paternal affective disorder before birth of the
10
11 index child, in children born to fathers with a history of affective disorder, there was
12
13 no association between paternal SSRIs use before conception and ASD in the
14
15 offspring (model 2: aHR=1.10, 95%CI: 0.61-1.98). For children whose father without
16
17 affective disorder, the patterns of associations remained similar to those of the main
18
19 analyses (Table 3).
20
21

22
23 In the sibling analysis, we identified 5,479 families with more than one child and
24
25 with at least one child with paternal SSRIs use before conception (Table 4). The risk
26
27 of ASD in exposed children was decreased when compared with their unexposed
28
29 siblings (aHR=0.74, 95%CI:0.34-1.59), although with wider confidence interval.
30
31

32 33 **Discussion**

34
35 In this large population-based cohort study, we observed an increased risk of ASD in
36
37 the offspring following paternal use of SSRIs during the last 3 months prior to
38
39 conception. However, the risk attenuated after adjusting for a number of potential
40
41 confounders, especially fathers' psychiatric conditions. When extending the exposure
42
43 window to one year before conception, the ASD risk persisted among children born to
44
45 former users but not current users. In addition, among children born to father with
46
47 affective disorder, no association was observed. Finally, we performed a sibling
48
49 analysis which allowed for better control of unmeasured familial confounding and the
50
51 decreased ASD risk was found among exposed children rather than their unexposed
52
53
54
55
56
57
58
59
60

1
2
3 siblings. Taken as a whole, our results did not support that paternal SSRIs use before
4
5
6 conception could increase the risk of ASD in children.
7

8
9
10 Recently, concerns have been raised regarding the risk of ASD in the offspring
11 associated with prenatal exposure to SSRIs. Four previous human studies have
12 suggested that in utero exposure to antidepressants would increase the risk of ASD in
13 children²¹⁻²⁴, although another two studies using the Danish registers have reported no
14 significant association^{38,39}. Basic neuro-biologic studies have showed that prenatal
15 SSRIs administration may be part of a causal pathway to ASD by operating directly
16 on the developing brain^{40,41}. Considering the detrimental effect of SSRIs on sperm^{28,}
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Recently, concerns have been raised regarding the risk of ASD in the offspring associated with prenatal exposure to SSRIs. Four previous human studies have suggested that in utero exposure to antidepressants would increase the risk of ASD in children²¹⁻²⁴, although another two studies using the Danish registers have reported no significant association^{38,39}. Basic neuro-biologic studies have showed that prenatal SSRIs administration may be part of a causal pathway to ASD by operating directly on the developing brain^{40,41}. Considering the detrimental effect of SSRIs on sperm^{28, 29, 42}, paternal SSRIs use before conception may also cause adverse effects on pregnancy outcomes. However, till now, only one study have suggested that SSRIs administration to male rats could induce deterioration in fertility and fetal outcomes (including weight gain, organ weights and feed consumption)⁴³. To our knowledge, our study is the first to investigate the link between paternal antidepressants use before conception and ASD risk in children. Considering the limited number of ASD cases and the challenges posed by confounding, further studies are needed to corroborate the findings.

In the present study, the increased risk of ASD observed in former users but not in current users implied that indications for paternal SSRIs use may account for the observed association between paternal SSRIs use and ASD in children, which was supported by previous studies suggesting that parental depression and other psychiatric disorders might be associated with the risk of autism in children⁴⁴⁻⁴⁶.

1
2
3
4 Therefore, similar to those studies which focused on the effect of maternal
5
6 antidepressants use during pregnancy, confounding by indication poses the main
7
8 challenge in our study. We adopted several analytic strategies to account for such
9
10 confounding by indication: (1) regression adjustment for paternal psychiatric
11
12 disorders; (2) negative controls (i.e., former-users analyses); (3) stratified analyses
13
14 according to paternal history of affective disorders; and (4) sibling analyses. The
15
16 results of these analyses suggested that paternal psychiatric illness rather than SSRIs
17
18 exposure might be associated with ASD liability. It was worth noting that, in children
19
20 born to fathers without affective disorders, there was a significantly increased risk
21
22 associated with paternal SSRIs use. Most fathers might receive SSRIs treatment from
23
24 their general practitioner and were therefore not registered with a diagnosis of
25
26 affective disorders in the hospital system. Therefore, it was possible that the increased
27
28 risk associated with prenatal SSRIs use was partly confounded by paternal affective
29
30 disorders diagnosed outside a hospital department for which we were not able to
31
32 adjust. In addition, other psychiatric diseases related to SSRIs use might also
33
34 contribute to the observed association.
35
36
37
38
39
40
41
42

43 Our study has several methodological strengths. One strength was that the linkage
44
45 of several nationwide health registries in Denmark enabled us to conduct a large
46
47 cohort study with virtually complete follow-up. The definition on exposure to SSRIs
48
49 was based on a national registry, which eliminated the risk of recall bias caused by
50
51 self-report. Another strength was that the information on ASD diagnosis was obtained
52
53 independently of exposure measurement, which could also mitigate the information
54
55
56
57
58
59
60

1
2
3 bias. Furthermore, the availability of health registry data enabled us to adjust for a
4
5 number of potential confounders including sociodemographic factors as well as
6
7 parental psychiatric history. Besides, we have taken the potential effect of maternal
8
9 antidepressants use during pregnancy as well as maternal mental disease into
10
11 consideration. To remove the confounding factors attributing to mothers, we adjusted
12
13 the maternal SSRIs use in regression model, and also restricted the analyses to
14
15 children whose mothers neither received antidepressant medication during pregnancy
16
17 nor had affective disorders before child birth.
18
19
20
21
22

23 Limitations need to be considered when interpreting the results of our study. Firstly,
24
25 we were unable to validate actual use of SSRIs by fathers during the time period of
26
27 interest because we relied on medical records of dispensed prescriptions. This may
28
29 lead to misclassification of exposure status because some people may not take the
30
31 medication or may take it later. Nevertheless, the misclassification was most likely
32
33 non-differential, which could bias the association toward null. Besides, some patients
34
35 may receive SSRIs treatment during inpatient admissions which are not included in
36
37 the prescription registry. We expect this problem to be minor since those inpatients
38
39 usually have severe psychiatric disorders and are more likely to continue treatment
40
41 after discharge. Secondly, the 3-month cut-off point was set based on the fact that
42
43 spermatogenesis takes approximately 70-90 days in humans. Whereas it may be
44
45 possible that SSRIs drugs induce sperm damage at the very primitive stage. However,
46
47 the results did not change markedly after extending the putative exposure period to
48
49 the last 6 months prior to conception (data not shown). Thirdly, ASD in children was
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 ascertained through the DNPR and the DPCRR, which did not include those children
5
6 who received the diagnosis of ASD from private psychiatrists or remained
7
8 undiagnosed at the end of the follow-up. However, the prevalence of ASD in our
9
10 cohort was 1.13%, which was similar to that reported in the United States during the
11
12 study period (1.14%)⁴⁷. Hence the bias introduced by case identification was
13
14 expected to be minimal. Fourthly, the age of ASD diagnosis which was used as time
15
16 event in Cox regression models might be affected by external and extraneous factors.
17
18 If these factors are differentially distributed in exposed and unexposed group, the
19
20 actual associations may be biased. We have adjusted for some factors which may
21
22 influence age of diagnosis to reduce the bias to some extent. However, we could not
23
24 rule out the confounding effects of unmeasured factors, which is a limitation of the
25
26 study.
27
28
29
30
31

32 33 **Conclusions**

34
35 In the study, paternal SSRI use before conception was associated with an increased
36
37 risk of ASD in the offspring, especially in the former users who took SSRIs over the
38
39 longer term. However, null association were observed in exposed children with
40
41 paternal affective disorders, and similar ASD risk were observed among exposed and
42
43 unexposed siblings, which implicates that paternal underlying indications related to
44
45 SSRIs use or other unmeasured confounding factors may explain the increased risk.
46
47
48

49 **Footnotes**

50
51 This cohort study was approved by the Danish Data Protection Agency (Document No.
52
53 2013-41-2569).
54
55
56
57
58
59
60

1
2
3
4 **Contributors:** HL had full access to all the data in the study and took responsibility
5
6 for the integrity of the data and the accuracy of the data analysis. HL, WY and JL
7
8 conceptualized and designed the study, and MHM and VE helped with its
9
10 development. FY, LL and JPC conducted the statistical analysis. HL, JPC and FY
11
12 interpreted the results and FY drafted the initial manuscript. All authors reviewed the
13
14 manuscript and approved the final version as submitted.
15
16

17
18 **Funding:** The study was supported by the National Natural Science Foundation of
19
20 China (81428011), the National Key Research and Development Program of China
21
22 (2016YFC1000505), the European Research Council
23
24 (ERC-2010-StG-260242-PROGEURO), Nordic Cancer Union (176673,186200),
25
26 Danish Council for Independent Research (DFF-6110-00019), Karen Elise Jensens
27
28 Fond (2016), and the Program for Clinical Research Infrastructure (PROCRIN)
29
30 established by the Lundbeck Foundation and the Novo Nordisk Foundation.
31
32

33
34
35 **Competing interests:** The authors declare that they have no conflict of interest.
36
37

38 **Statement of the independence of researchers from funders:** The funding sources
39
40 had no role in the design and conduct of the study; collection, management, analysis,
41
42 and interpretation of the data; and preparation, review, or approval of the manuscript;
43
44 and decision to submit the manuscript for publication. The researchers were
45
46 independent from the funders.
47
48

49
50 **Ethical approval:** The study was based on secondary data. No individuals were
51
52 approached as a result of the study, nor did we access any other data from the
53
54 participants. This study was approved by the Danish Data Protection Agency
55
56
57

(Document No. 2013-41-2569). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval by an institutional review board and informed consent are not required for registry-based research in Denmark.

Data sharing statement: No additional data are available.

Reference

1. Organization WH. Depression [fact sheet no. 369]. 2012. As of September. 2015;30.
2. Alwan S, Friedman JM, Chambers C. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. *CNS drugs*. 2016;30(6):499-515.
3. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. *American journal of obstetrics and gynecology*. 2006;194(4):961-966.
4. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. *Archives of pediatrics & adolescent medicine*. 2009;163(10):949-954.
5. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. *Bmj*. 2009;339:b3569.
6. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. *Archives of pediatrics & adolescent medicine*. 2007;161(1):22-29.
7. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *American Journal of Psychiatry*. 2012;169(11):1165-1174.
8. Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence. *International Journal of Risk & Safety in Medicine*. 2016;28(3):125-141.
9. Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. *Molecular psychiatry*. 2015;20(6):727-734.
10. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. *JAMA pediatrics*. 2016;170(2):117-124.
11. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link? *Medical Hypotheses*. 2010;74(5):880-883.
12. Brown HK, Ray JG, Wilton AS, et al. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. *Jama*. 2017;317(15):1544-1552.
13. Sujan AC, Rickert ME, Öberg AS, et al. Associations of Maternal Antidepressant Use During the

1
2
3 First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
4 and Attention-Deficit/Hyperactivity Disorder in Offspring. *Jama*. 2017;317(15):1553-1562.

5 14. Oberlander TF, Zwaigenbaum L. Disentangling Maternal Depression and Antidepressant Use
6 During Pregnancy as Risks for Autism in Children. *Jama*. 2017;317(15):1533-1534.

7 15. Mezzacappa A, Lasica P-A, Gianfagna F, et al. Risk for Autism Spectrum Disorders According to
8 Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis. *JAMA pediatrics*.
9 2017.

10 16. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a
11 population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *The*
12 *lancet*. 2006;368(9531):210-215.

13 17. Rutter M. Incidence of autism spectrum disorders: Changes over time and their meaning*. *Acta*
14 *paediatrica*. 2005;94(1):2-15.

15 18. Hill AP, Zuckerman K, Fombonne E. Epidemiology of autism spectrum disorders. *Translational*
16 *Approaches to Autism Spectrum Disorder*: Springer 2015:13-38.

17 19. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders*.
18 *Annu Rev Public Health*. 2007;28:235-258.

19 20. Brown HK, Hussain-Shamsy N, Lunskey Y, et al. The association between antenatal exposure to
20 selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. *The Journal*
21 *of clinical psychiatry*. 2017;78(1):e48.

22 21. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors
23 and risk for autism spectrum disorder. *Journal of autism and developmental disorders*.
24 2014;44(10):2558-2567.

25 22. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood
26 autism spectrum disorders. *Archives of general psychiatry*. 2011;68(11):1104-1112.

27 23. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during
28 pregnancy, and risk of autism spectrum disorders: population based case-control study. 2013.

29 24. Rai D, Lee BK, Dalman C, et al. Antidepressants during pregnancy and autism in offspring:
30 population based cohort study. *Bmj*. 2017;358:j2811.

31 25. Schirm E, Pedersen L, Tobi H, et al. Drug use among fathers around time of conception: two
32 register based surveys from Denmark and The Netherlands. *Pharmacoepidemiology and drug safety*.
33 2004;13(9):609-613.

34 26. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers
35 before and during pregnancy. A population - based cohort study of 106 000 pregnancies in Norway
36 2004 - 2006. *British journal of clinical pharmacology*. 2008;65(5):653-660.

37 27. Crijns I, Bos J, Knol M, et al. Paternal drug use: before and during pregnancy. *Expert opinion on*
38 *drug safety*. 2012;11(4):513-518.

39 28. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. *Fertility and*
40 *sterility*. 2010;94(3):1021-1026.

41 29. Safarinejad MR. Sperm DNA damage and semen quality impairment after treatment with
42 selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure
43 assay. *The Journal of urology*. 2008;180(5):2124-2128.

44 30. Lewis S, Aitken R. DNA damage to spermatozoa has impacts on fertilization and pregnancy. *Cell*
45 *and tissue research*. 2005;322(1):33-41.

46 31. Pedersen CB, Gøtzsche H, Møller JØ, et al. The Danish civil registration system. *Dan Med Bull*.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 2006;53(4):441-449.
32. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Danish medical bulletin*. 1998;45(3):320-323.
33. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scandinavian journal of public health*. 2011;39(7 suppl):38-41.
34. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. *Basic & clinical pharmacology & toxicology*. 2008;102(2):176-181.
35. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. *Scandinavian journal of public health*. 2011;39(7 suppl):54-57.
36. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. *Danish medical bulletin*. 1999;46(3):263-268.
37. Lauritsen MB, Jørgensen M, Madsen KM, et al. Validity of childhood autism in the Danish Psychiatric Central Register: findings from a cohort sample born 1990–1999. *Journal of autism and developmental disorders*. 2010;40(2):139-148.
38. Christensen J, Parner ET, Vestergaard M. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. *Clinical epidemiology*. 2013;5:449-459.
39. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. *New England Journal of Medicine*. 2013;369(25):2406-2415.
40. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. *Neuropsychopharmacology*. 2006;31(1):47-57.
41. Bonnin A, Levitt P. Fetal, maternal and placental sources of serotonin and new implications for developmental programming of the brain. *Neuroscience*. 2011;197:1.
42. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. *Urology*. 2007;69(1):185. e185-185. e187.
43. Elmazoudy R, Abdelhameed N, Elmasry A. Paternal dapoxetine administration induced deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male rats. *International Journal of Impotence Research*. 2015;27(6).
44. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism spectrum disorders in the offspring. *Pediatrics*. 2008;121(5):e1357-e1362.
45. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. *American journal of epidemiology*. 2005;161(10):916-925.
46. Jokiranta E, Brown AS, Heinimaa M, et al. Parental psychiatric disorders and autism spectrum disorders. *Psychiatry research*. 2013;207(3):203-211.
47. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. *Pediatrics*. 2009;124(5):1395-1403.

Table 1. Baseline Characteristics of the study population

Characteristic	Paternal SSRIs use during the last 3 months prior to conception (N=6,870)	No paternal SSRIs use during the last 3 months prior to conception (N=663, 052)
Calendar Year of birth, No. (%)		
1998-2000	1,021(14.9)	185,784(28.0)
2001-2003	1,526(22.2)	179,952(27.1)
2004-2006	2,305(33.5)	178,664(27.0)
2007-2008	2,018(29.4)	118,652(17.9)
Gender, No. (%)		
Boy	3,549(51.7)	340,194(51.3)
Girl	3,321(48.3)	322,858(48.7)
Birth Weight (g), No. (%)		
<2500	278(4.1)	22,315(3.4)
2500-3250	1,729(25.2)	154,494(23.3)
3250-4000	3,582(52.1)	348,853(52.6)
4000-8000	1,243(18.1)	132,343(19.9)
Unknown	38(0.5)	5,047(0.8)
Parity, No. (%)		
1	2,693(39.2)	282,895(42.7)
2	2,433(35.4)	250,496(37.8)
≥3	1,744(25.4)	129,661(19.5)
Preterm Birth, No. (%) (<37 weeks)		
No	6,489(94.4)	630,851(95.1)
Yes	381(5.6)	32,201(4.9)
Apgar score at 5 minutes, No. (%)		
0-7	91(1.3)	8,224(1.2)
8-9	442(6.4)	39,941(6.0)
10	6,269(91.3)	607,634(91.7)
Unknown	68(1.0)	7,253(1.1)
Maternal age at child birth (years), No. (%)		
≤25	958(13.9)	99,273(15.0)
26-30	2,238(32.6)	244,419(36.9)
31-35	2,386(34.7)	225,610(34.0)
>35	1,288(18.8)	93,750(14.1)
Paternal age at child birth (years), No. (%)		
≤25	364(5.3)	47,490(7.2)
26-30	1,434(20.9)	180,612(27.2)
31-35	2,395(34.8)	242,702(36.6)
>35	2,677(39.0)	192,248(29.0)

Table 1. Baseline Characteristics of the study population (continued)

Maternal smoking status^a, No. (%)		
No	4,326(63.0)	477,574(72.0)
Yes	1,334(19.4)	106,233(16.0)
Unknown	1,210(17.6)	79,245(12.0)
Maternal AD use during pregnancy, No. (%)		
No	6,548(94.0)	653,496(98.6)
Yes	412(6.0)	9,556(1.4)
Maternal history of Affective disorder, No. (%)		
No	6,607(96.2)	654,234(98.7)
Yes	263(3.8)	8,818(1.3)
Paternal history of Affective disorder, No. (%)		
No	6,099 (88.8)	659,639(99.5)
Yes	771(11.2)	3,413(0.5)
Maternal history of psychiatric disorder, No. (%)		
No	6,175(89.9)	626,840(94.5)
Yes	695(10.1)	36,212(5.5)
Paternal history of psychiatric disorder, No. (%)		
No	5,092 (74.1)	630,990(95.2)
Yes	1,178(25.9)	32,062(4.8)

Abbreviations: SSRI, selective serotonin reuptake inhibitor; N, number; AD, antidepressant drugs;

^a Maternal smoking information was missing among those children born from 2007 to 2008.

Table 2. Association between paternal SSRIs use before conception and ASD in offspring

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,473	6,765,205	Ref	Ref	Ref
Use during the last 3 months prior to conception	104	61,555	1.62(1.33-1.96)	1.54(1.27-1.88)	1.43(1.18-1.74)
Sub-analysis:					
Paternal SSRIs use during the last 1 year before conception					
No use during the last 1 year prior to conception	7,429	6,736,654	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	71	39,422	1.71(1.35-2.16)	1.66(1.31-2.09)	1.54(1.21-1.94)
Use only during the last 3 months prior to conception	20	14,738	1.29(0.83-2.00)	1.24 (0.80-1.93)	1.17(0.75-1.82)
Use both before and during the last 3 months prior to conception	57	35,946	1.52(1.17-1.97)	1.43(1.10-1.86)	1.32(1.02-1.72)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 3. Association between paternal SSRIs use before conception and ASD in offspring born to fathers diagnosed with affective disorder or not

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Fathers with affective disorder					
No use during the last 3 months prior to conception	58	30,908	Ref	Ref	Ref
Use during the last 3 months prior to conception	14	6,625	1.17(0.65-2.09)	1.10(0.61-1.98)	1.10(0.61-1.98)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	53	28,033	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	8	4,082	1.07(0.51-2.25)	1.08(0.51-2.30)	1.08(0.51-2.30)
Use only during the last 3 months prior to conception	2	1,164	0.91(0.22-3.75)	0.89(0.21-3.75)	0.89(0.21-3.75)
Use both before and during the last 3 months prior to conception	9	4,254	1.16(0.57-2.35)	1.10(0.55-2.22)	1.10(0.55-2.22)
Fathers without affective disorder					
No use during the last 3 months prior to conception	7,415	6,752,899	Ref	Ref	Ref
Use during the last 3 months prior to conception	90	36,329	1.57(1.27-1.93)	1.52(1.23-1.87)	1.45(1.18-1.79)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	7,376	6,714,926	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	63	37,973	1.69(1.32-2.17)	1.64(1.28-2.11)	1.57(1.23-2.02)
Use only during the last 3 months prior to conception	18	7,354	1.26(0.79-2.00)	1.23(0.77-1.95)	1.19(0.75-1.88)
Use both before and during the last 3 months prior to conception	48	28,974	1.45(1.09-1.93)	1.38(1.04-1.84)	1.32(0.99-1.76)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 4. Paternal SSRI use before pregnancy and ASD in exposed and unexposed siblings from 5,479 families

Paternal SSRIs use before conception	Number of offspring no.	Offspring with ASD no.	Hazard Ratio (95% CI)	
			Crude	Model 1 ^a
No use during the last 3 months prior to conception	2,792	45	Ref	Ref
Use during the last 3 months prior to conception	2,687	23	0.53(0.31-0.91)	0.74(0.34-1.59)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for sex, parity, mother age, father age, maternal smoking, maternal AD use during pregnancy

TablesS1. Association between paternal SSRIs use before conception and ASD in offspring: analyses stratified by gender

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Boys					
No use during the last 3 months prior to conception	6,005	3,459,592	Ref	Ref	Ref
Use during the last 3 months prior to conception	84	31,642	1.61(1.30-2.00)	1.55(1.25-1.92)	1.44(1.16-1.79)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	5,969	3,444,956	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	58	20,031	1.74(1.34-2.25)	1.69(1.30-2.19)	1.58(1.22-2.05)
Use only during the last 3 months prior to conception	18	7,622	1.42(0.89-2.26)	1.39(0.87-2.21)	1.31(0.83-2.09)
Use both before and during the last 3 months prior to conception	44	18,623	1.44 (1.07-1.93)	1.36(1.01-1.84)	1.26(0.94-1.71)
Girls					
No use during the last 3 months prior to conception	1,468	3,305,613	Ref	Ref	Ref
Use during the last 3 months prior to conception	20	29,914	1.63(1.05-2.53)	1.54(0.99-2.40)	1.41(0.90-2.20)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	1,460	3,291,698	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	13	19,390	1.61(0.93-2.78)	1.53(0.88-2.64)	1.37(0.79-2.38)
Use only during the last 3 months prior to conception	2	7,116	0.67(0.17-2.69)	0.64(0.16-2.55)	0.59(0.15-2.36)
Use both before and during the last 3 months prior to conception	13	75,323	1.84(1.06-3.17)	1.74(1.01-3.01)	1.59(0.92-2.75)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table S2. Association between paternal SSRIs use before conception and ASD in offspring born to mother who neither received antidepressants medication during pregnancy nor had affective disorders before birth of child

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,184	6,627,720	Ref	Ref	Ref
Use during the last 3 months prior to conception	91	57,081	1.55(1.26-1.91)	1.57(1.28-1.93)	1.45(1.18-1.79)
Sub-analysis:					
Paternal SSRIs use during the last 1 year before conception					
No use during the last 1 year prior to conception	7,144	6,600,852	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	64	37,032	1.67(1.30-2.13)	1.68(1.31-2.15)	1.56(1.22-1.99)
Use only during the last 3 months prior to conception	16	13,634	1.13(0.69-1.85)	1.15(0.71-1.89)	1.08(0.66-1.77)
Use both before and during the last 3 months prior to conception	51	33,283	1.50(1.13-1.97)	1.50(1.13-1.97)	1.38(1.05-1.82)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history

^b Model 1 further adjusted for father psychiatric history

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	8-10
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	9-10

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	22
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-11
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016368.R3
Article Type:	Research
Date Submitted by the Author:	10-Nov-2017
Complete List of Authors:	<p>Yang, Fen; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science; Aarhus Universitetshospital, Department of Clinical Epidemiology</p> <p>Chen, Jianping; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science</p> <p>Miao, Mao-Hua; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Yuan, Wei; Shanghai Institute of Planned Parenthood Research, Reproductive Epidemiology, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Li, Lin; Shanghai Institute of Planned Parenthood Research</p> <p>Liang, Hong; Shanghai Institute of Planned Parenthood Research, Department of Reproductive Epidemiology and Social Science, National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices</p> <p>Ehrenstein, Vera; Aarhus Universitetshospital</p> <p>Li, Jiong; Aarhus Universitetshospital, Department of Clinical Epidemiology</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Mental health
Keywords:	MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, NEUROPATHOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Risk of autism spectrum disorder in offspring following paternal use of selective**
4 **serotonin reuptake inhibitors before conception: a population-based cohort**
5
6 **study**
7
8
9

10 Fen Yang^{1,2}; Jianping Chen¹; Maohua Miao¹; Wei Yuan¹; Lin Li¹; Hong Liang¹; Vera
11 Ehrenstein²; Jiong Li²
12
13
14
15

16
17
18 **Author Affiliation**
19

20 ¹Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
21 Shanghai, 200032, China
22
23

24 ²Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle
25 43-45, DK-8200 Aarhus N, Denmark
26
27
28
29

30
31
32
33 **Corresponding Author**
34

35 Hong Liang, MD, PhD
36

37 Key Lab. of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University,
38 #779 Lao Hu Min Road, Shanghai, 200032, China.
39
40

41 Email: lucylhcn@163.com;
42

43 Phone number: 86 -21-64771683
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective

The present study aimed to examine the association between paternal selective serotonin reuptake inhibitors (SSRIs) use before conception and the risk of autism spectrum disorder (ASD) in offspring.

Design

A population-based cohort study

Methods

We conducted a cohort study of 669,922 children born from 1998 to 2008, with follow-up throughout 2013. Based on Danish national registers, we linked information on paternal use of SSRIs, ASD diagnosed in children, and a range of potential confounders. The children whose fathers used SSRIs during the last 3 months prior to conception were identified as the exposed. Cox regression model was used to estimate the hazard ratio (HR) for ASD in children.

Results

Compared with unexposed children, the exposed had a 1.62-fold higher risk of ASD (95% confidence interval [CI]: 1.33-1.96) and the risk attenuated after adjusting for potential confounders, especially fathers' psychiatric conditions (HR=1.43, 95% CI: 1.18-1.74). When extending the exposure window to 1 year before conception, the increased risk persisted in children of fathers using SSRIs only from the last year till the last 3 months prior to conception (HR=1.54, 95%CI: 1.21-1.94) but not in children of fathers using SSRIs only during the last 3 months prior to conception

1
2
3 (HR=1.17, 95%CI: 0.75-1.82). We also performed stratified analyses according to
4
5
6 paternal history of affective disorders and observed no increased ASD risk among
7
8 children whose father had affective disorders. Besides, the sibling analysis showed
9
10 that the ASD risk did not increase among exposed children compared with their
11
12 unexposed siblings.
13
14

15 **Conclusions**

16
17
18 The mildly increased risk of ASD in the offspring associated with paternal SSRIs use
19
20 before conception may be attributable to paternal underlying psychiatric indications
21
22 related to SSRIs use or other unmeasured confounding factors.
23
24
25
26
27
28
29

30 **Strengths and limitations of this study**

- 31
32
33
34 ● This is the very first study that investigates the association between paternal
35 antidepressants use and ASD risk in children.
36
37 ● A number of potential confounders, including sociodemographic factors as well as
38 parental psychiatric history, can be adjusted for based on the availability of
39 national health registry data.
40
41 ● Actual use of SSRIs by fathers during the time period of interest may not be
42 validated.
43
44 ● Those children who received the diagnosis of ASD from private psychiatrists or
45 remained undiagnosed at the end of the follow-up may not be identified as ASD
46 case.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Depression is a common mental health problem that affects approximately 350 million people worldwide¹. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and other anxiety-related disorders. However, an increasing body of evidence suggests that prenatal exposure to SSRIs is associated with adverse obstetrical and neonatal outcomes²⁻⁵. In addition, recent studies have indicated a possible link between prenatal SSRI exposure and neurobehavioral problems in children^{2, 6-10}, which may be due to the biological mechanisms (i.e. dysfunctional serotonin signaling)¹¹. Whereas several studies have suggested that the previously observed association between prenatal SSRI exposure and neurodevelopmental diseases might be due to confounding by related indications¹²⁻¹⁵.

Autism spectrum disorder (ASD) is one of the major neurodevelopmental disorders characterized by impairments in reciprocal social interaction, communication, and repetitive or stereotypic behavior¹⁶. The estimated prevalence of ASD has dramatically increased from less than 1 in 2,000 children in the 1960s to approximately 1 in 145 children today^{17, 18}. Both genetic and environmental risk factors may contribute to ASD¹⁹. Recently, maternal use of SSRIs during pregnancy has been reported to be associated with an increased risk of ASD in children^{10, 20-24}.

If maternal SSRI exposure during pregnancy plays a role in fetal, even in child's, development, an extended effect of earlier exposure on gamete, particularly human sperm, is biologically plausible. Therefore, the potential role of paternal SSRI use in

1
2
3 ASD should also be taken into consideration. Studies in the Nordic countries show
4
5 that one-third of the fathers used prescription drugs during the last 6 months prior to
6
7 conception²⁵, and approximately 1.4% of fathers were dispensed SSRIs during the
8
9 last 3 months prior to conception^{26, 27}. Although the information regarding the
10
11 potential effects of SSRI use by fathers is limited, the hypothesis of an increased risk
12
13 of adverse pregnancy or neonatal outcome associated with paternal drug exposure is
14
15 not new. Several human studies have indicated the adverse effects of paternal SSRIs
16
17 use, including impaired semen quality and abnormal sperm DNA fragmentation,
18
19 which has been reported to be associated with diminished fertility, adverse pregnancy
20
21 outcomes (like pregnancy loss), and an increased risk of childhood disease²⁸⁻³⁰.
22
23
24
25
26
27

28 Little is known on whether paternal SSRIs use before conception contributes to
29
30 the risk of ASD in offspring. We conducted a population-based cohort study to
31
32 examine the association between paternal SSRIs use during the last 3 months prior to
33
34 conception and risk of ASD in offspring, utilizing data from national Danish health
35
36 registries.
37
38
39

40 **Methods**

41 **Study Population**

42
43 This study was based on several national registers in Denmark. Each Danish resident
44
45 is assigned a unique personal identification number (a 10-digit civil registration
46
47 system number used in all registries), which enables accurate linkage of national
48
49 registries at the individual level³¹. The Danish Medical Birth Registry (DMBR)
50
51 contains records of all deliveries in Denmark since 1973 and includes information
52
53
54
55
56
57
58
59
60

1
2
3
4 about gestational age at birth from 1978³². Using the DMBR data, we identified a
5
6 cohort of all singletons born alive in Denmark during the period of January 1, 1998
7
8 through December 31, 2008 (n=687,580). We excluded children without linkage to
9
10 their father (n=16,955) or their mother (n=74), with missing parity (n=208), and with
11
12 missing or extreme values of gestational age (≤ 23 weeks or ≥ 45 weeks, n=421). A
13
14 total of 669,922 children were included in the analysis.
15
16

17 **Data on SSRIs use**

18
19 Information on SSRIs use was drawn from the Danish National Prescription Registry
20
21 (DNPR)³³. Since 1995, this registry has recorded all redeemed prescriptions in
22
23 Denmark with the following information: the civil registration number of the patient,
24
25 the dispensing date, the medication code (the WHO Anatomical Therapeutic Chemical
26
27 (ATC) classification system), the number of packages prescribed, and the number of
28
29 doses units in package. Selective serotonin reuptake inhibitors use was identified
30
31 based on ATC codes: fluoxetine (N06AB03), citalopram (N06AB04), paroxetine
32
33 (N06AB05), sertraline (N06AB06), fluvoxamine (N06AB08), and escitalopram
34
35 (N06AB10). It is estimated that spermatogenesis takes approximately 74 days³⁴,
36
37 therefore we chose the last 3 months prior to conception as the exposure window to
38
39 cover the susceptible time period. A child was considered exposed if the dispensing
40
41 date fell within the specified exposure window or the number of days for which the
42
43 SSRIs medication was supplied overlapped any portion of the exposure window.
44
45 Children born to fathers who had no prescriptions for SSRIs and no supply overlap
46
47 during the entire exposure window were considered unexposed. The date of
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conception was estimated by subtracting gestational age from the date of delivery.
4
5
6 Data on paternal SSRIs use during the last two years prior to the conception were
7
8 extracted for further analyses. We also retrieved the information about maternal SSRIs
9
10 use during the pregnancy.
11
12

13 **Autism spectrum disorders**

14
15 Autism spectrum disorders in children were identified by using the Danish Psychiatric
16
17 Central Research Register (DPCRR) and the Danish National Patient Register
18
19 (DNPR). The DPCRR contains diagnostic information on every admission from
20
21 psychiatric hospitals and psychiatric wards in general hospitals in Denmark since
22
23 1969, and includes data on all outpatient visits and emergency room contacts since
24
25 1995³⁵. The DNPR has collected data on all inpatients from all somatic hospitals in
26
27 Denmark since 1977 and outpatients from 1995³⁶. The combined data from the two
28
29 registries were used to identify all children diagnosed with ASD. During the study
30
31 period, the diagnosis of ASD was based on the International Classification of
32
33 Diseases, 10th version (ICD-10) codes of F84.0 (Childhood autism), F84.1 (Atypical
34
35 autism), F84.5 (Asperger syndrome), F84.8 (other pervasive developmental
36
37 disorders) and F84.9 (unspecified pervasive developmental disorders). The quality of
38
39 the childhood autism diagnosis has been validated and the diagnoses could be
40
41 verified in 94% of the children with a record in the DPCRR³⁷. Children were
42
43 followed up from birth till first diagnosis of ASD, death, emigration, or December 31,
44
45 2013, whichever came first.
46
47
48
49
50
51
52
53

54 **Covariates**

Using the Danish nationwide health registers, we retrieved data on characteristics that may be associated with offspring ASD or paternal SSRIs use. For each child, we obtained information on calendar year of birth, gender of the child, birth weight, Apgar score at 5 minutes, gestational age, maternal parity, maternal age at child birth, paternal age at child birth and maternal smoking status during pregnancy from the DMBR. Parents' psychiatric history prior to birth of the index child was obtained from DPCRR by ICD-8 codes 290-315 from 1977 to 1993 and ICD-10 codes F00-F99 from 1994 onward. Furthermore, we identified parents diagnosed with affective disorders before birth of child (specifically, ICD-8 codes 296.09, 296.19, 296.29, 296.39, 296.99, 298.09, 298.19, 300.49, and 301.19, and ICD-10 codes F30-F34 and F38-F39) using the DPCRR.

Statistical Analysis

Cox proportional-hazards regression models (using child's calendar age in years as the underlying timescale) were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of ASD in children following exposure to paternal SSRIs use before conception. Observations were censored if the child died or emigrated before the end of follow-up.

We adjusted for variables as following: the calendar year of birth (1998-2000, 2001-2003, 2004-2006, 2007-2008), gender of the child (boy, girl), parity (1, 2, ≥ 3), parental age at child birth (≤ 25 , 26-30, 31-35, and > 35 years), maternal smoking status during pregnancy (yes or no), maternal history of psychiatric disorders before birth of child (yes or no), maternal antidepressants use during pregnancy (yes or no)

1
2
3 in model 1. We additionally adjusted for paternal history of psychiatric disorders
4 before birth of child (yes or no) in model 2. Models were also run with the exclusion
5
6 of those children with missing data for covariates. The proportional hazard
7
8 assumption was evaluated for all variables included in the adjusted model by
9
10 comparing estimated log-minus-log survival curves.
11
12
13
14

15
16 To distinguish the direct effects of SSRIs use from the effects of the indication of
17
18 SSRIs use, we extended the exposure window to 1 year before conception. We then
19
20 re-categorized the exposed children into three subgroups: children of fathers who used
21
22 SSRIs 1) only from the last year till the last 3 months prior to conception (former
23
24 users); 2) only during the last 3 months prior to conception (current short-term users,
25
26 hereinafter referred to as ‘current users’); 3) both before and during the last 3 months
27
28 prior to conception (both former and current users). The reference group consisted of
29
30 those children born to fathers who never used SSRIs medication through the last year
31
32 before conception.
33
34
35
36

37
38 The stratified analysis was performed to examine whether the association between
39
40 paternal SSRIs use and ASD in children differed by gender. We also restricted the
41
42 analyses to children whose mothers neither received antidepressant medication during
43
44 pregnancy nor had affective disorder before birth of child. To further distinguish the
45
46 effect of SSRIs medication from that of the main indication (i.e., affective disorders)
47
48 for SSRIs treatment, we performed stratified analyses according to paternal history of
49
50 affective disorder before birth of the index child. As for those children born to fathers
51
52 with affective disorders, the ASD risk we examined could be solely attributable to
53
54
55
56
57
58
59
60

1
2
3 paternal SSRIs use since both of the exposed children and the reference children were
4
5
6 with paternal affective disorders.
7

8 To control for unmeasured family-related confounding factors (such as genetic
9
10 liability for neuropsychiatric conditions and early postnatal environmental influences),
11
12 we conducted sibling-matched analyses by only including the families with
13
14 exposure-discordant siblings, in which there was at least one child with paternal
15
16 SSRIs preconception exposure and one child without exposure. Using the stratified
17
18 Cox proportional-hazards regression with a separate stratum for each family, we
19
20
21 estimated the association between paternal SSRIs use before conception and ASD in
22
23 matched sets of exposure-discordant siblings. In the stratified Cox regression model,
24
25
26 we also adjusted for those covariates that varied among siblings with the same father
27
28 (including parental age at conception, maternal parity, smoking, and maternal AD use
29
30 during pregnancy).
31
32
33
34

35 All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary,
36
37 North Carolina, USA).
38
39

40 **Results**

41
42 Among the 669,922 singletons included in the study, 6,870 (1.03%) children were
43
44 born to fathers who had redeemed a prescription for SSRIs during the last 3 months
45
46 prior to conception. During the study period, a total of 7,577 children were diagnosed
47
48 with ASD. The median age at diagnosis of ASD was 6.77 years (interquartile range:
49
50 4.84 to 9.48 years). Characteristics of the study population are shown in Table 1.
51
52
53 Compared with the unexposed group, there were a higher proportion of exposed
54
55
56
57
58
59
60

1
2
3 children born in later calendar years. Fathers in exposed group were more likely to be
4
5 older at child birth and to have a history of psychiatric disorder (including affective
6
7 disorder) before birth of child. Mothers of exposed children were characterized as
8
9 having higher parity, being more likely to be older at child birth, to use
10
11 antidepressants during pregnancy, and to have a history of psychiatric disorder before
12
13 birth of child.
14
15
16
17

18 Among 61,555 person-years of follow-up, we identified 104 cases of ASD in
19
20 children born to fathers who used SSRIs during the last 3 months prior to conception
21
22 (incidence rate: 169 per 100,000 person-years). This incidence rate corresponded to a
23
24 62% increased risk of ASD compared with the unexposed group (Table 2). The
25
26 adjusted HR (aHR) of ASD was 1.54 (95% CI: 1.27-1.88) after adjusting for potential
27
28 confounders in model 1. After paternal psychiatric history was further adjusted for in
29
30 model 2, the estimate was 1.43 (95%CI: 1.18-1.74). When extending the exposure
31
32 window to the last one year prior to conception, after the full adjustment, the HR for
33
34 ASD in children of fathers who were former users only and who were both former
35
36 and current users was 1.54 (95%CI: 1.21-1.94) and 1.32 (95%CI: 1.02-1.72),
37
38 respectively. However, the increased risk decreased and became nonsignificant among
39
40 children of fathers who were only current users (aHR=1.17, 95%CI: 0.75-1.82, model
41
42 2, table2).
43
44
45
46
47
48
49

50 The risk estimates of ASD were similar for both boys and girls, regardless of the
51
52 exposure (Table S1). When we restricted analyses to children whose mothers neither
53
54
55
56
57
58
59
60

1
2
3 used SSRIs during pregnancy nor had affective disorder before birth of child, the
4
5
6 results did not change essentially (Table S2).
7

8
9 When the analyses were stratified by paternal affective disorder before birth of the
10
11 index child, in children born to fathers with a history of affective disorder, there was
12
13 no association between paternal SSRIs use before conception and ASD in the
14
15 offspring (model 2: aHR=1.10, 95%CI: 0.61-1.98). For children whose father without
16
17 affective disorder, the patterns of associations remained similar to those of the main
18
19 analyses (Table 3).
20
21

22
23 In the sibling analysis, we identified 5,479 families with more than one child and
24
25 with at least one child with paternal SSRIs use before conception (Table 4). The risk
26
27 of ASD in exposed children was decreased when compared with their unexposed
28
29 siblings (aHR=0.74, 95%CI:0.34-1.59), although with wider confidence interval.
30
31

32 33 **Discussion**

34
35 In this large population-based cohort study, we observed an increased risk of ASD in
36
37 the offspring following paternal use of SSRIs during the last 3 months prior to
38
39 conception. However, the risk attenuated after adjusting for a number of potential
40
41 confounders, especially fathers' psychiatric conditions. When extending the exposure
42
43 window to one year before conception, the ASD risk persisted among children born to
44
45 former users but not current users. In addition, among children born to father with
46
47 affective disorder, no association was observed. Finally, we performed a sibling
48
49 analysis which allowed for better control of unmeasured familial confounding and the
50
51 decreased ASD risk was found among exposed children rather than their unexposed
52
53
54
55
56
57
58
59
60

1
2
3 siblings. Taken as a whole, our results did not support that paternal SSRIs use before
4
5
6 conception could increase the risk of ASD in children.
7

8
9
10 Recently, concerns have been raised regarding the risk of ASD in the offspring
11 associated with prenatal exposure to SSRIs. Four previous human studies have
12 suggested that in utero exposure to antidepressants would increase the risk of ASD in
13 children²¹⁻²⁴, although another two studies using the Danish registers have reported no
14 significant association^{38,39}. Basic neuro-biologic studies have showed that prenatal
15 SSRIs administration may be part of a causal pathway to ASD by operating directly
16 on the developing brain^{40,41}. Considering the detrimental effect of SSRIs on sperm^{28,}
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Recently, concerns have been raised regarding the risk of ASD in the offspring associated with prenatal exposure to SSRIs. Four previous human studies have suggested that in utero exposure to antidepressants would increase the risk of ASD in children²¹⁻²⁴, although another two studies using the Danish registers have reported no significant association^{38,39}. Basic neuro-biologic studies have showed that prenatal SSRIs administration may be part of a causal pathway to ASD by operating directly on the developing brain^{40,41}. Considering the detrimental effect of SSRIs on sperm^{28, 29, 42}, paternal SSRIs use before conception may also cause adverse effects on pregnancy outcomes. However, till now, only one study have suggested that SSRIs administration to male rats could induce deterioration in fertility and fetal outcomes (including weight gain, organ weights and feed consumption)⁴³. To our knowledge, our study is the first to investigate the link between paternal antidepressants use before conception and ASD risk in children. Considering the limited number of ASD cases and the challenges posed by confounding, further studies are needed to corroborate the findings.

In the present study, the increased risk of ASD observed in former users but not in current users implied that indications for paternal SSRIs use may account for the observed association between paternal SSRIs use and ASD in children, which was supported by previous studies suggesting that parental depression and other psychiatric disorders might be associated with the risk of autism in children⁴⁴⁻⁴⁶.

1
2
3
4 Therefore, similar to those studies which focused on the effect of maternal
5
6 antidepressants use during pregnancy, confounding by indication poses the main
7
8 challenge in our study. We adopted several analytic strategies to account for such
9
10 confounding by indication: (1) regression adjustment for paternal psychiatric
11
12 disorders; (2) negative controls (i.e., former-users analyses); (3) stratified analyses
13
14 according to paternal history of affective disorders; and (4) sibling analyses. The
15
16 results of these analyses suggested that paternal psychiatric illness rather than SSRIs
17
18 exposure might be associated with ASD liability. It was worth noting that, in children
19
20 born to fathers without affective disorders, there was a significantly increased risk
21
22 associated with paternal SSRIs use. Most fathers might receive SSRIs treatment from
23
24 their general practitioner and were therefore not registered with a diagnosis of
25
26 affective disorders in the hospital system. Therefore, it was possible that the increased
27
28 risk associated with prenatal SSRIs use was partly confounded by paternal affective
29
30 disorders diagnosed outside a hospital department for which we were not able to
31
32 adjust. In addition, other psychiatric diseases related to SSRIs use might also
33
34 contribute to the observed association.
35
36
37
38
39
40
41
42

43 Our study has several methodological strengths. One strength was that the linkage
44
45 of several nationwide health registries in Denmark enabled us to conduct a large
46
47 cohort study with virtually complete follow-up. The definition on exposure to SSRIs
48
49 was based on a national registry, which eliminated the risk of recall bias caused by
50
51 self-report. Another strength was that the information on ASD diagnosis was obtained
52
53 independently of exposure measurement, which could also mitigate the information
54
55
56
57
58
59
60

1
2
3 bias. Furthermore, the availability of health registry data enabled us to adjust for a
4
5 number of potential confounders including sociodemographic factors as well as
6
7 parental psychiatric history. Besides, we have taken the potential effect of maternal
8
9 antidepressants use during pregnancy as well as maternal mental disease into
10
11 consideration. To remove the confounding factors attributing to mothers, we adjusted
12
13 the maternal SSRIs use in regression model, and also restricted the analyses to
14
15 children whose mothers neither received antidepressant medication during pregnancy
16
17 nor had affective disorders before child birth.
18
19
20
21
22

23 Limitations need to be considered when interpreting the results of our study. Firstly,
24
25 we were unable to validate actual use of SSRIs by fathers during the time period of
26
27 interest because we relied on medical records of dispensed prescriptions. This may
28
29 lead to misclassification of exposure status because some people may not take the
30
31 medication or may take it later. Nevertheless, the misclassification was most likely
32
33 non-differential, which could bias the association toward null. Besides, some patients
34
35 may receive SSRIs treatment during inpatient admissions which are not included in
36
37 the prescription registry. We expect this problem to be minor since those inpatients
38
39 usually have severe psychiatric disorders and are more likely to continue treatment
40
41 after discharge. Secondly, the 3-month cut-off point was set based on the fact that
42
43 spermatogenesis takes approximately 70-90 days in humans. Whereas it may be
44
45 possible that SSRIs drugs induce sperm damage at the very primitive stage. However,
46
47 the results did not change markedly after extending the putative exposure period to
48
49 the last 6 months prior to conception (data not shown). Thirdly, ASD in children was
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ascertained through the DNPR and the DPCRR, which did not include those children
4
5
6 who received the diagnosis of ASD from private psychiatrists or remained
7
8 undiagnosed at the end of the follow-up. However, the prevalence of ASD in our
9
10 cohort was 1.13%, which was similar to that reported in the United States during the
11
12 study period (1.14%)⁴⁷. Hence the bias introduced by case identification was
13
14 expected to be minimal. Fourthly, the age of ASD diagnosis which was used as time
15
16 event in Cox regression models might be affected by external and extraneous factors.
17
18 If these factors are differentially distributed in exposed and unexposed group, the
19
20 actual associations may be biased. We have adjusted for some factors which may
21
22 influence age of diagnosis to reduce the bias to some extent. However, we could not
23
24 rule out the confounding effects of unmeasured factors, which is a limitation of the
25
26 study.
27
28
29
30
31

32 **Conclusions**

33
34
35 In the study, paternal SSRI use before conception was associated with an increased
36
37 risk of ASD in the offspring, especially in the former users who took SSRIs over the
38
39 longer term. However, null association were observed in exposed children with
40
41 paternal affective disorders, and similar ASD risk were observed among exposed and
42
43 unexposed siblings, which implicates that paternal underlying indications related to
44
45 SSRIs use or other unmeasured confounding factors may explain the increased risk.
46
47
48

49 **Footnotes**

50
51 This cohort study was approved by the Danish Data Protection Agency (Document No.
52
53 2013-41-2569).
54
55
56
57
58
59
60

1
2
3 **Contributors:** HL had full access to all the data in the study and took responsibility
4
5 for the integrity of the data and the accuracy of the data analysis. HL, WY and JL
6
7 conceptualized and designed the study, and MHM and VE helped with its
8
9 development. FY, LL and JPC conducted the statistical analysis. HL, JPC and FY
10
11 interpreted the results and FY drafted the initial manuscript. All authors reviewed the
12
13 manuscript and approved the final version as submitted.
14
15

16
17 **Funding:** The study was supported by the National Natural Science Foundation of
18
19 China (81428011), the National Key Research and Development Program of China
20
21 (2016YFC1000505), the European Research Council
22
23 (ERC-2010-StG-260242-PROGEURO), Nordic Cancer Union (176673,186200),
24
25 Danish Council for Independent Research (DFF-6110-00019), Karen Elise Jensens
26
27 Fond (2016), and the Program for Clinical Research Infrastructure (PROCRIN)
28
29 established by the Lundbeck Foundation and the Novo Nordisk Foundation.
30
31

32
33 **Competing interests:** The authors declare that they have no conflict of interest.
34
35

36
37 **Statement of the independence of researchers from funders:** The funding sources
38
39 had no role in the design and conduct of the study; collection, management, analysis,
40
41 and interpretation of the data; and preparation, review, or approval of the manuscript;
42
43 and decision to submit the manuscript for publication. The researchers were
44
45 independent from the funders.
46
47

48
49 **Ethical approval:** The study was based on secondary data. No individuals were
50
51 approached as a result of the study, nor did we access any other data from the
52
53 participants. This study was approved by the Danish Data Protection Agency
54
55

(Document No. 2013-41-2569). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval by an institutional review board and informed consent are not required for registry-based research in Denmark.

Data sharing statement: No additional data are available.

Reference

1. Organization WH. Depression [fact sheet no. 369]. 2012. As of September. 2015;30.
2. Alwan S, Friedman JM, Chambers C. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. *CNS drugs*. 2016;30(6):499-515.
3. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. *American journal of obstetrics and gynecology*. 2006;194(4):961-966.
4. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. *Archives of pediatrics & adolescent medicine*. 2009;163(10):949-954.
5. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. *Bmj*. 2009;339:b3569.
6. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. *Archives of pediatrics & adolescent medicine*. 2007;161(1):22-29.
7. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *American Journal of Psychiatry*. 2012;169(11):1165-1174.
8. Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence. *International Journal of Risk & Safety in Medicine*. 2016;28(3):125-141.
9. Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. *Molecular psychiatry*. 2015;20(6):727-734.
10. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. *JAMA pediatrics*. 2016;170(2):117-124.
11. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link? *Medical Hypotheses*. 2010;74(5):880-883.
12. Brown HK, Ray JG, Wilton AS, et al. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. *Jama*. 2017;317(15):1544-1552.
13. Sujan AC, Rickert ME, Öberg AS, et al. Associations of Maternal Antidepressant Use During the

- 1
2
3 First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
4 and Attention-Deficit/Hyperactivity Disorder in Offspring. *Jama*. 2017;317(15):1553-1562.
- 5 14. Oberlander TF, Zwaigenbaum L. Disentangling Maternal Depression and Antidepressant Use
6 During Pregnancy as Risks for Autism in Children. *Jama*. 2017;317(15):1533-1534.
- 7 15. Mezzacappa A, Lasica P-A, Gianfagna F, et al. Risk for Autism Spectrum Disorders According to
8 Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis. *JAMA pediatrics*.
9 2017.
- 10 16. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a
11 population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *The*
12 *lancet*. 2006;368(9531):210-215.
- 13 17. Rutter M. Incidence of autism spectrum disorders: Changes over time and their meaning*. *Acta*
14 *paediatrica*. 2005;94(1):2-15.
- 15 18. Hill AP, Zuckerman K, Fombonne E. Epidemiology of autism spectrum disorders. *Translational*
16 *Approaches to Autism Spectrum Disorder: Springer* 2015:13-38.
- 17 19. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders*.
18 *Annu Rev Public Health*. 2007;28:235-258.
- 19 20. Brown HK, Hussain-Shamsy N, Lunskey Y, et al. The association between antenatal exposure to
20 selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. *The Journal*
21 *of clinical psychiatry*. 2017;78(1):e48.
- 22 21. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors
23 and risk for autism spectrum disorder. *Journal of autism and developmental disorders*.
24 2014;44(10):2558-2567.
- 25 22. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood
26 autism spectrum disorders. *Archives of general psychiatry*. 2011;68(11):1104-1112.
- 27 23. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during
28 pregnancy, and risk of autism spectrum disorders: population based case-control study. 2013.
- 29 24. Rai D, Lee BK, Dalman C, et al. Antidepressants during pregnancy and autism in offspring:
30 population based cohort study. *Bmj*. 2017;358:j2811.
- 31 25. Schirm E, Pedersen L, Tobi H, et al. Drug use among fathers around time of conception: two
32 register based surveys from Denmark and The Netherlands. *Pharmacoepidemiology and drug safety*.
33 2004;13(9):609-613.
- 34 26. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers
35 before and during pregnancy. A population - based cohort study of 106 000 pregnancies in Norway
36 2004 - 2006. *British journal of clinical pharmacology*. 2008;65(5):653-660.
- 37 27. Crijns I, Bos J, Knol M, et al. Paternal drug use: before and during pregnancy. *Expert opinion on*
38 *drug safety*. 2012;11(4):513-518.
- 39 28. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. *Fertility and*
40 *sterility*. 2010;94(3):1021-1026.
- 41 29. Safarinejad MR. Sperm DNA damage and semen quality impairment after treatment with
42 selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure
43 assay. *The Journal of urology*. 2008;180(5):2124-2128.
- 44 30. Lewis S, Aitken R. DNA damage to spermatozoa has impacts on fertilization and pregnancy. *Cell*
45 *and tissue research*. 2005;322(1):33-41.
- 46 31. Pedersen CB, Gøtzsche H, Møller JØ, et al. The Danish civil registration system. *Dan Med Bull*.

- 2006;53(4):441-449.
32. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Danish medical bulletin*. 1998;45(3):320-323.
33. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scandinavian journal of public health*. 2011;39(7 suppl):38-41.
34. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. *Basic & clinical pharmacology & toxicology*. 2008;102(2):176-181.
35. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. *Scandinavian journal of public health*. 2011;39(7 suppl):54-57.
36. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. *Danish medical bulletin*. 1999;46(3):263-268.
37. Lauritsen MB, Jørgensen M, Madsen KM, et al. Validity of childhood autism in the Danish Psychiatric Central Register: findings from a cohort sample born 1990–1999. *Journal of autism and developmental disorders*. 2010;40(2):139-148.
38. Christensen J, Parner ET, Vestergaard M. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. *Clinical epidemiology*. 2013;5:449-459.
39. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. *New England Journal of Medicine*. 2013;369(25):2406-2415.
40. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. *Neuropsychopharmacology*. 2006;31(1):47-57.
41. Bonnin A, Levitt P. Fetal, maternal and placental sources of serotonin and new implications for developmental programming of the brain. *Neuroscience*. 2011;197:1.
42. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. *Urology*. 2007;69(1):185. e185-185. e187.
43. Elmazoudy R, Abdelhameed N, Elmasry A. Paternal dapoxetine administration induced deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male rats. *International Journal of Impotence Research*. 2015;27(6).
44. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism spectrum disorders in the offspring. *Pediatrics*. 2008;121(5):e1357-e1362.
45. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. *American journal of epidemiology*. 2005;161(10):916-925.
46. Jokiranta E, Brown AS, Heinimaa M, et al. Parental psychiatric disorders and autism spectrum disorders. *Psychiatry research*. 2013;207(3):203-211.
47. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. *Pediatrics*. 2009;124(5):1395-1403.

Table 1. Baseline Characteristics of the study population

Characteristic	Paternal SSRIs use during the last 3 months prior to conception (N=6,870)	No paternal SSRIs use during the last 3 months prior to conception (N=663, 052)
Calendar Year of birth, No. (%)		
1998-2000	1,021(14.9)	185,784(28.0)
2001-2003	1,526(22.2)	179,952(27.1)
2004-2006	2,305(33.5)	178,664(27.0)
2007-2008	2,018(29.4)	118,652(17.9)
Gender, No. (%)		
Boy	3,549(51.7)	340,194(51.3)
Girl	3,321(48.3)	322,858(48.7)
Birth Weight (g), No. (%)		
<2500	278(4.1)	22,315(3.4)
2500-3250	1,729(25.2)	154,494(23.3)
3250-4000	3,582(52.1)	348,853(52.6)
4000-8000	1,243(18.1)	132,343(19.9)
Unknown	38(0.5)	5,047(0.8)
Parity, No. (%)		
1	2,693(39.2)	282,895(42.7)
2	2,433(35.4)	250,496(37.8)
≥3	1,744(25.4)	129,661(19.5)
Preterm Birth, No. (%) (<37 weeks)		
No	6,489(94.4)	630,851(95.1)
Yes	381(5.6)	32,201(4.9)
Apgar score at 5 minutes, No. (%)		
0-7	91(1.3)	8,224(1.2)
8-9	442(6.4)	39,941(6.0)
10	6,269(91.3)	607,634(91.7)
Unknown	68(1.0)	7,253(1.1)
Maternal age at child birth (years), No. (%)		
≤25	958(13.9)	99,273(15.0)
26-30	2,238(32.6)	244,419(36.9)
31-35	2,386(34.7)	225,610(34.0)
>35	1,288(18.8)	93,750(14.1)
Paternal age at child birth (years), No. (%)		
≤25	364(5.3)	47,490(7.2)
26-30	1,434(20.9)	180,612(27.2)
31-35	2,395(34.8)	242,702(36.6)
>35	2,677(39.0)	192,248(29.0)

Table 1. Baseline Characteristics of the study population (continued)

Maternal smoking status^a, No. (%)		
No	4,326(63.0)	477,574(72.0)
Yes	1,334(19.4)	106,233(16.0)
Unknown	1,210(17.6)	79,245(12.0)
Maternal AD use during pregnancy, No. (%)		
No	6,548(94.0)	653,496(98.6)
Yes	412(6.0)	9,556(1.4)
Maternal history of Affective disorder, No. (%)		
No	6,607(96.2)	654,234(98.7)
Yes	263(3.8)	8,818(1.3)
Paternal history of Affective disorder, No. (%)		
No	6,099 (88.8)	659,639(99.5)
Yes	771(11.2)	3,413(0.5)
Maternal history of psychiatric disorder, No. (%)		
No	6,175(89.9)	626,840(94.5)
Yes	695(10.1)	36,212(5.5)
Paternal history of psychiatric disorder, No. (%)		
No	5,092 (74.1)	630,990(95.2)
Yes	1,178(25.9)	32,062(4.8)

Abbreviations: SSRI, selective serotonin reuptake inhibitor; N, number; AD, antidepressant drugs;

^a Maternal smoking information was missing among those children born from 2007 to 2008.

Table 2. Association between paternal SSRIs use before conception and ASD in offspring

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,473	6,765,205	Ref	Ref	Ref
Use during the last 3 months prior to conception	104	61,555	1.62(1.33-1.96)	1.54(1.27-1.88)	1.43(1.18-1.74)
Sub-analysis:					
Paternal SSRIs use during the last 1 year before conception					
No use during the last 1 year prior to conception	7,429	6,736,654	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	71	39,422	1.71(1.35-2.16)	1.66(1.31-2.09)	1.54(1.21-1.94)
Use only during the last 3 months prior to conception	20	14,738	1.29(0.83-2.00)	1.24 (0.80-1.93)	1.17(0.75-1.82)
Use both before and during the last 3 months prior to conception	57	35,946	1.52(1.17-1.97)	1.43(1.10-1.86)	1.32(1.02-1.72)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 3. Association between paternal SSRIs use before conception and ASD in offspring born to fathers diagnosed with affective disorder or not

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Fathers with affective disorder					
No use during the last 3 months prior to conception	58	30,908	Ref	Ref	Ref
Use during the last 3 months prior to conception	14	6,625	1.17(0.65-2.09)	1.10(0.61-1.98)	1.10(0.61-1.98)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	53	28,033	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	8	4,082	1.07(0.51-2.25)	1.08(0.51-2.30)	1.08(0.51-2.30)
Use only during the last 3 months prior to conception	2	1,164	0.91(0.22-3.75)	0.89(0.21-3.75)	0.89(0.21-3.75)
Use both before and during the last 3 months prior to conception	9	4,254	1.16(0.57-2.35)	1.10(0.55-2.22)	1.10(0.55-2.22)
Fathers without affective disorder					
No use during the last 3 months prior to conception	7,415	6,752,899	Ref	Ref	Ref
Use during the last 3 months prior to conception	90	36,329	1.57(1.27-1.93)	1.52(1.23-1.87)	1.45(1.18-1.79)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	7,376	6,714,926	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	63	37,973	1.69(1.32-2.17)	1.64(1.28-2.11)	1.57(1.23-2.02)
Use only during the last 3 months prior to conception	18	7,354	1.26(0.79-2.00)	1.23(0.77-1.95)	1.19(0.75-1.88)
Use both before and during the last 3 months prior to conception	48	28,974	1.45(1.09-1.93)	1.38(1.04-1.84)	1.32(0.99-1.76)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

Table 4. Paternal SSRI use before pregnancy and ASD in exposed and unexposed siblings from 5,479 families

Paternal SSRIs use before conception	Number of offspring no.	Offspring with ASD no.	Hazard Ratio (95% CI)	
			Crude	Model 1 ^a
No use during the last 3 months prior to conception	2,792	45	Ref	Ref
Use during the last 3 months prior to conception	2,687	23	0.53(0.31-0.91)	0.74(0.34-1.59)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for sex, parity, mother age, father age, maternal smoking, maternal AD use during pregnancy

TablesS1. Association between paternal SSRIs use before conception and ASD in offspring: analyses stratified by gender

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
Boys					
No use during the last 3 months prior to conception	6,005	3,459,592	Ref	Ref	Ref
Use during the last 3 months prior to conception	84	31,642	1.61(1.30-2.00)	1.55(1.25-1.92)	1.44(1.16-1.79)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	5,969	3,444,956	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	58	20,031	1.74(1.34-2.25)	1.69(1.30-2.19)	1.58(1.22-2.05)
Use only during the last 3 months prior to conception	18	7,622	1.42(0.89-2.26)	1.39(0.87-2.21)	1.31(0.83-2.09)
Use both before and during the last 3 months prior to conception	44	18,623	1.44 (1.07-1.93)	1.36(1.01-1.84)	1.26(0.94-1.71)
Girls					
No use during the last 3 months prior to conception	1,468	3,305,613	Ref	Ref	Ref
Use during the last 3 months prior to conception	20	29,914	1.63(1.05-2.53)	1.54(0.99-2.40)	1.41(0.90-2.20)
<i>Sub-analysis:</i>					
<i>Paternal SSRIs use during the last 1 year before conception</i>					
No use during the last 1 year prior to conception	1,460	3,291,698	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	13	19,390	1.61(0.93-2.78)	1.53(0.88-2.64)	1.37(0.79-2.38)
Use only during the last 3 months prior to conception	2	7,116	0.67(0.17-2.69)	0.64(0.16-2.55)	0.59(0.15-2.36)
Use both before and during the last 3 months prior to conception	13	75,323	1.84(1.06-3.17)	1.74(1.01-3.01)	1.59(0.92-2.75)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy

^b Model 1 further adjusted for father psychiatric history

TableS2. Association between paternal SSRIs use before conception and ASD in offspring born to mother who neither received antidepressants medication during pregnancy nor had affective disorders before birth of child

Paternal SSRIs use before conception	Offspring with ASD no.	Follow-up no. of person-yr	Hazard Ratio (95% CI)		
			Crude	Model 1 ^a	Model 2 ^b
No use during the last 3 months prior to conception	7,184	6,627,720	Ref	Ref	Ref
Use during the last 3 months prior to conception	91	57,081	1.55(1.26-1.91)	1.57(1.28-1.93)	1.45(1.18-1.79)
Sub-analysis:					
Paternal SSRIs use during the last 1 year before conception					
No use during the last 1 year prior to conception	7,144	6,600,852	Ref	Ref	Ref
Use only from the last 1 year to the last 3 months prior to conception	64	37,032	1.67(1.30-2.13)	1.68(1.31-2.15)	1.56(1.22-1.99)
Use only during the last 3 months prior to conception	16	13,634	1.13(0.69-1.85)	1.15(0.71-1.89)	1.08(0.66-1.77)
Use both before and during the last 3 months prior to conception	51	33,283	1.50(1.13-1.97)	1.50(1.13-1.97)	1.38(1.05-1.82)

Abbreviations: AD, antidepressant drugs; SSRI, selective serotonin reuptake inhibitor; ASD, Autism Spectrum Disorder; No., number; HR, Hazard Ratio

^a Adjusted for calendar year of birth, parity, mother age, father age, maternal smoking, mother psychiatric history

^b Model 1 further adjusted for father psychiatric history

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	8-10
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	9-10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	22
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-11
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.